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INTRODUCTION 
 
 
URINARY INCONTINENCE: OVERVIEW 
 
Urinary incontinence (UI) is defined by the International Continence 
Society (ICS) as “the complaint of any involuntary leakage of urine” (Abrams et 
al, 2003). Stress urinary incontinence (SUI) is defined by the same society as 
“the complaint of involuntary leakage on effort or exertion, or on sneezing or 
coughing” (Abrams et al, 2003). Urinary incontinence is the most prevalent 
pelvic floor disorder (Lukacz et al, 2006 and Coyne et al, 2009) and is 
responsible for silent suffering and social ostracism.  
It is a highly prevalent complaint among women living in Western 
countries, with mean overall reports around 35% of women in large 
epidemiological surveys, SUI being the most common type of urine loss 
(Hunskaar et al, 2004 and Coyne et al, 2009). Estimates of the annual direct 
costs of UI, in a 1995 study, are around $16 billion (in United States dollars) 
(Wilson et al, 2001). More recently, another American study described that 
community-dwelling women with severe forms of UI pay up to $1150 (in United 
States dollars) per year out-of-pocket for incontinence routine care (Subak et al, 
2007).  
Current surgical treatment options are driven by our better understanding 
of SUI causal mechanisms. The continence mechanism is obtained by the 
fixation of the middle region of the urethra to the pubic bone, via the 
pubourethral ligaments and the adequate positioning of the urethra by the 
11 
 
muscle and ligamentory elements of the pelvic brim, assuring adequate 
coaptation of the urethra wall during coughing or sneezing. The loss of this 
mechanism results in urethral hypermobility. This integral theory of female 
incontinence, described in 1990 (Petros et al, 1990), remains one of the most 
important concepts that defines the modern approach to anti-incontinence 
surgery. The clinical applications of these concepts are evident in the tension-
free positioning of the urethral slings in a location beneath the mid-urethra, 
which reinforces muscle insertion points, ligaments, restores opening and 
closing muscle forces and, therefore, function (Lee et al, 2010). 
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SURGERY IS THE IDEAL FORM OF TREATMENT 
 
Although being a very prevalent condition, seek for professional help, 
even in western countries, is very low, with consultation rates of 31% (Hunskaar 
et al, 2004). Active forms of treatment are, unfortunately, requested only by a 
small fraction of the affected women, with half of them using absorbable pads 
as the form of treatment (Hunskaar et al, 2004).  
Conservative treatments are the first management step and include 
behavioural interventions, life-style changes, pelvic-floor muscle training, 
pharmacologic treatment and medical devices. Physical exercise and weight 
reduction can cure up to 27% of the overweight patients with SUI, but requires a 
prolonged program of diet and exercise, which demands a firm adherence and 
will not produce readily perceptible improvement (Subak et al, 2009). 
Pelvic floor muscle training (PFMT) is a first-line therapy for women with 
SUI (Hay-Smith, 2008). PFMT can improve continence in the majority of 
patients, but cure rates are very low (around 20%) and seen particularly in 
younger patients with mild forms of SUI (Hay-Smith, 2008 and Shamliyan et al, 
2008). These treatments are time-consuming, require a firm and long-lasting 
adherence and their durability is questioned (European Association of Urology, 
2013). A recent randomized clinical trial (RCT) comparing treatment of female 
SUI with initial mid-urethral sling surgery versus initial physiotherapy largely 
favoured the surgical treatment, with higher subjective, objective cured and 
improved rates at 1 year follow-up (Labrie et al, 2013). Even in the long run, 
PFMT does not have an important impact on SUI cure, since the vast majority 
of women incontinent at one trial entry also reported SUI at 12 years follow-up 
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and more women in the PFMT group have been submitted to surgical SUI 
treatment (Glazener et al, 2014). 
Pharmacologic treatment of SUI is still limited. Duloxetine is a serotonin 
and nor-epinephrine reuptake inhibitor. The increase of these two 
neurotransmitters in the spinal cord (Onuf’s nucleus), intensifies the pudendal 
nerve activity, increasing the resting and contraction tone of the urethral 
sphincter (Li et al, 2013). However, in a recent meta-analysis, duloxetine is only 
marginally better than placebo to cure SUI (7.8% versus 10.8), while causing 
high rates of side-effects (Li et al, 2013). According to the European Association 
of Urology (EAU) Guidelines on Urinary Incontinence, duloxetine should not be 
offered to women who are seeking a cure for their incontinence. 
 The use of local oestrogens may improve urinary incontinence, 
particularly in post-menopausal women, although timing, duration, type and 
route of administration are not clearly defined. Also, long-term effects are not 
known, as studies are few and not designed to address this matter, as recently 
has been reported by a Cochrane review (Cody et al, 2012). On the other hand, 
systemic use of oestrogens may worsen incontinence (Cody et al, 2012). 
Concerns about the risk of endometrial and breast cancer after long-term use of 
systemic oestrogen suggest that treatment should be for limited periods, 
especially in those women with an intact uterus (Cody et al, 2012). 
 
It is therefore without surprise that the EAU Guidelines on Urinary 
Incontinence peremptory state that the most effective treatment of female SUI is 
the insertion of a synthetic mid-urethral sling (MUS), which gives equivalent 
patient-reported cure of SUI, when compared to colposuspension, but at much 
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lower costs, short and long term complications and time to return to normal 
activity (European Association of Urology, 2013). These guidelines also report 
that mid-urethral synthetic sling inserted by either the transobturator (TO) or 
retropubic (RP) route gives equivalent patient-reported outcome at 12 months 
(European Association of Urology, 2013). 
Peri-urethral and trans-urethral injection of bulking agents is considered 
by many authors to be a surgical form of SUI treatment. Some studies show 
promising results in some groups of patients, but evidence for its use is lacking 
(Kirchin et al, 2012). Consensus indicates that bulking agents should not be 
offered to women who are seeking for a permanent SUI cure (European 
Association of Urology, 2013), or that are fit for other surgical procedures 
(Kirchin et al, 2012). 
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MID-URETHRAL SLINGS: INCONVENIENCES AND COMPLICATIONS 
 
The swift success of the mid-urethral tension-free vaginal tape (TVT™, 
Gynecare, Ethicon, Somerville, New Jersey, USA) (Ulmsten et al, 1996) can be 
estimated by the 1 million cases that had been performed worldwide during the 
first 10 years that elapsed after its introduction by Ulmsten et al, in the middle 
1990’s (Deng et al, 2007 and Schimpf et al, 2014). Although considered a safe 
procedure, TVT™ has, nevertheless been associated with severe 
complications, such as bladder and bowel perforations and life-threatening 
vascular injuries. These complications are associated with the blind passage of 
the needles through the RP space (Deng et al, 2007 and Novara et al, 2008). 
This prompted the development of the TO route, by Delorme et al, to reduce 
RP-route associated complications (Delorme et al, 2004). Large randomized 
studies comparing the RP against the TO route established that the two 
techniques are virtually identical concerning SUI cure, with a percentage of 
objective cured patients in the range between 75 and 80% (Rechberger et al, 
2009 and Richter et al, 2010). However, TO slings did not decrease all 
complications, but rather replaced those associated with the incursion through 
the RP space by others caused by the violation of the obturator foramen. 
Transobturator tapes have been associated with prolonged and limitative pain 
referred to the groin and upper thigh, due to peripheral nerve injury and vaginal 
perforations due to a more horizontal trajectory of the needle passage (Deng et 
al, 2007; Novara et al, 2008 and Richter et al, 2010). In addition, vascular 
complications and severe perineal fasciitis were occasionally reported (Deng et 
al, 2007). 
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 As MUS surgeries, performed by the RP or TO route, are currently the 
preferred surgical treatment worldwide, with millions of women submitted to 
these surgeries, it is important to describe complications and morbidity 
associated with these procedures. 
Complications associated with MUS can be divided into intra-operative, 
peri-operative and post-operative ones (Costantini et al, 2007) or according to 
the nature or type of complication (Novara et al, 2008). 
 
Hemorrhagic Complications 
 
Hemorrhage is relatively rare. Hemorrhage, defined as blood loss greater 
than 200 mL or postoperative hematoma, occurs in approximately 2% of 
patients and can usually be managed by observation or local compression. A 
recent prospective randomized study comparing the adverse effects after RP 
and TO MUS surgery reported that intra-operative blood loss (more than 100 
mL) was one of the most common intra-operative complication in both surgery 
groups and occurred twice as frequently in the RP group (4.7% versus 2.3%) 
(Brubaker et al, 2011).  
Catastrophic complications do occur after RP MUS and may result in 
mortality, as seven reported deaths exist in the database from 1998 to 2005 
(Food and Drug Administration, 2014). Major vascular injuries have not been 
reported in TO MUS procedures, probably due to the anatomy of TO MUS 
needle passage (Moore et al, 2007).  
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Injury to the lower urinary tract 
 
Complications consisting of injury to the lower urinary tract (LUT) are 
bladder perforation and urethral injury. The bladder perforation rate was 
reported to be between 2.9 and 5% in one large national registry (Kuuva and 
Nilson, 2002) of RP MUS procedures, although there are reports that reach 
23% of cases (Andonian et al, 2005). In a meta-analysis, the numbers are 
consistently below 10% (Novara et al, 2008). The risk of complications was 
higher in centres where RP MUS are occasionally performed (Kuuva and 
Nilson, 2002). A recent review assessing the evidence on the effectiveness and 
complications of RP and TO procedures reported that bladder perforation was 
significantly more common in the RP group (Long et al, 2009). A recent RCT 
comparing adverse effects after RP and TO MUS surgery reported that intra-
operative bladder perforation (5%) occurred exclusively in the RP group 
(Brubaker et al, 2011). In a recent Cochrane Review, the RP bottom-to-top 
route was more effective than top-to-bottom route and incurred in significantly 
less bladder perforations (Ogah et al, 2011). A recent retrospective review of 
patients undergoing RP MUS placement complicated by bladder perforation 
during sling placement showed that the majority of subjects (20 of 25 of 
patients) were successfully discharged home the day of surgery without 
catheter drainage (Crosby et al, 2013). This risk is much rarer in the TO than it 
is in RP procedures (Dmochowsky et al, 2007) because the planned trocar path 
during TO sling placement does not enter the pelvis. Case reports of bladder 
and urethral injuries have led to the current recommendation for routine intra-
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operative urethrocystoscopy (Minaglia et al, 2004), even with the use of the TO 
route (American Urological Association, 2009). 
Urethral lesion is a rare event. On a review article on this matter (Morton 
and Hill, 2009), the authors reported urethral perforation during RP procedures 
in about 0.5% (range 0-2.0%) of the cases and in 1% (range 0-2.5%) after TO 
procedures. 
 
Infectious complications 
 
The vast majority of the studies address only the most frequent infectious 
complication, in this case uncomplicated urinary tract infection, with a 
prevalence situated between 5.5 and 7.5%, and no statistical differences 
between the RP or the TO route (Rechberger et al 2009). These numbers are 
almost consistently below 10% (Novara et al, 2008). In a nationwide analysis of 
complications associated with TVTTM procedures (Kuuva and Nilsson, 2002), 
the authors reported that 4.1%, 0.8%, and 0.7% of patients had urinary tract 
infection, wound infection of the abdominal incision, and defective healing of the 
vaginal incision, respectively. Nevertheless, there are case series or single-
patient reports on serious and life-threatening necrotizing infectious (Johnson et 
al, 2003 and Connolly, 2004). It was speculated that the presence of localized 
infection and morbid obesity could be possible risk factors for the development 
of necrotizing infections. Serious infection-related complications after TO 
procedures have included thigh abscesses requiring drainage and an infected 
obturator hematoma also requiring exploration and drainage (Dmochowsky et 
al, 2007). 
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Mesh Extrusion 
 
Vaginal extrusion is a rare complication and its incidence is reported to 
range from 0.5% to 1.1% (Brubaker et al, 2011). Some possible reasons for 
vaginal extrusion include wound infection, impaired wound healing, superficial 
placement of the sling on the vaginal wall and vaginal atrophy (Tsivian et al, 
2004). Symptoms of vaginal erosion include vaginal discharge, a palpable 
rough surface in the vagina, sexual discomfort (usually partner related), and 
LUT symptoms, including hematuria. However, up to 35% of patients may be 
asymptomatic (Hammad et al, 2005), and the erosion only identified in vaginal 
examination. This complication is more frequent with the TO approach, reaching 
almost statistical significance in a recent meta-analysis (Ogah et al, 2009), with 
a Risk Ratio of 1.58 [0.83-3], although the highest incidence series reports a 4% 
vaginal erosion rate. Domingo et al (2005), who used ObtapeTM or UratapeTM as 
the sling material, reported a relatively high vaginal extrusion rate (15%). They 
attributed this high erosion rate to the reduced pore size of their mesh (50 µm). 
They concluded that synthetic mesh with larger pore sizes facilitated vascular 
and tissue ingrowth, thus optimizing mesh incorporation. Because of similar 
reports, currently, “when offering a synthetic mid-urethral tape procedure, 
surgeons should use a device manufactured from type 1 macroporous 
polypropylene tape” (NICE recommendations, 2013). 
The management options are not standardized and range from 
observation to partial and complete tape excision and re-approximation of the 
vaginal mucosa over the exposed tape (Costantini et al, 2007). Initial 
observation for small vaginal erosions, with the use of local oestrogens creams 
when appropriate is recommended, while excision should be preferred for large 
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erosions and those that do not respond to conservative treatment (Costantini et 
al, 2007). 
Urethral erosion is defined as the presence of sling material within the 
urethral lumen. The median rate of urethral erosions at RP tape procedures 
from 13 studies was 0.88% (range 0.1–5.5%) and for TO foramen tape 
procedures in ten studies was 1.09% (range 0.0–2.5%), showing there are not 
substantial differences (Morton and Hill, 2009). Excess tension of the sling on 
the urethra, and technical error during dissection of the plane underneath the 
urethra, resulting in compromised thickness of suburethral tissue, were 
advanced as possible risk factors for urethral erosion (Kobashi and Govier, 
2003). The erosion could also be a result of an unrecognized urethral 
perforation during the original procedure (Wai et al, 2004). The vast majority of 
patients are symptomatic (Costantini et al, 2007). Voiding dysfunction is 
predominant with symptoms of urgency, urge incontinence, obstructive voiding 
symptoms, and sometimes complete urinary retention. Recurrent urinary tract 
infection may be the clinical picture. Diagnosis is made by determining the 
presence of the tape within the urethral lumen during urethrocystoscopy. 
Conservative observational treatment is not an option. Endoscopic tape 
transection or transvaginal excision of the tape with closure of the urethrotomy 
is the treatment option (Madjar et al, 2002). A Martius fat pad graft may be used 
in case of extensive urethrotomies (Costantini et al, 2007). 
Intravesical tape erosion is the finding of sling material within the lumen 
of the bladder. The vast majority of this complication is due to inadvertent and 
unrecognized bladder perforation during the original procedure, usually using a 
RP route. Thus, complete and thorough cystoscopic evaluation by an 
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experienced urologist is essential to minimize this complication. Typical 
symptoms are intermittent gross hematuria, pelvic pain, storage-type LUT 
symptoms and recurrent UTI. Observational treatment is not an option. The 
sling material inside the bladder must be removed either endoscopically or by 
open surgery. Only patients with complete tape removal have been reported to 
have recurrent stress incontinence (Dmochowsky et al, 2007). 
 
Voiding dysfunction 
 
The presenting symptoms of voiding dysfunction (VD) may differ in terms 
of type and severity in a range between urinary frequency and urinary retention. 
A recent study evaluating the long-term results of TVTTM reported de 
novo overactive bladder symptoms in 30.1% and 18.9% of patients at 3 months 
and 10 years of follow-up, respectively (Serati et al, 2012). The incidence of 
postoperative VD varies between 2.1% and 6.7% after TO MUS (Dmochowsky 
et al, 2007). Although differences appear substantial, some meta-analysis of 
RCTs report similar rates of de novo urgency for both procedures, although 
urinary retention is marginally more common in women that underwent TVTTM 
(Long et al, 2009). After TO sling surgery, obstructive urinary symptoms are 
usually transient and are usually managed by short-term intermittent 
catheterization, although occasionally symptoms do not subside, thus making 
tape release mandatory. In a meta-analysis, postoperative urinary retention was 
found to be slightly more common in women undergoing RP MUS than in those 
undergoing TO MUS (Long et al, 2009). Brubaker et al (2011) also reported that 
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VD requiring surgery (and/or catheter use) was more common after RP MUS 
than after TO MUS.  
A recently reviewed 2009 extensive Cochrane Review on minimally 
invasive synthetic suburethral sling operations for female SUI statistically favors 
the TO route, when compared with the RP route, concerning de novo VD (Mean 
Risk Ratio of 0.63, [0.44-0.89]). Surprisingly, no statistical difference was 
proven when considering de novo detrusor overactivity, with a Mean Risk Ratio 
of 1.22 [0.56-2.63] (Ogah et al, 2009 and 2011). 
Urinary retention stands at the edge of the symptom spectrum of VD 
seen after MUS surgery. The definition of urinary retention after MUS varies 
between studies. It may be defined as catheter-dependency for at least 28 days 
(Patel et al, 2012). There is no consensus about the cut-off level of PVR after 
voiding trials that needs catheterization. For a clinically significant PVR, some 
authors propose 20% to 50% of the bladder capacity, whereas others use 
clearly defined levels of PVR ranging from 100 to 150 mL (Elliott and Comiter, 
2012). The discomfort of the patient also plays an important role in the decision 
making for clean intermittent or indwelling catheterization. Even though 
obstruction appears to be the main etiological factor, there is not a precise 
method for diagnosing obstruction, and subsequently predicting the patients 
who will benefit from a urethral release surgery (Carr and Webster, 1997; 
Petrou et al, 1999). Increased outlet resistance by the over-tensioned sling 
appears to be the main causative factor for urinary retention after MUS. It is still 
unclear whether preoperative urodynamic findings indicating relatively impaired 
detrusor contractility may predict postoperative retention. For example, 
Kleeman et al (2002) showed that a preoperatively high PVR was a significant 
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risk factor in predicting postoperative retention after different types of anti-
incontinence and prolapse surgeries. 
Urinary retention may be recognized when patients fail to empty their 
bladder at the first voiding attempt. Kim et al (2012) further showed that 
postoperative VD is common in the early postoperative period but may be 
transient and associated with the immediate voiding conditions following 
surgery such as increased fluid load and bladder overdistention. The latter 
study showed that that even among patients who fail the initial voiding trial, 
36.8% can successfully void on subsequent trials. When the patient cannot void 
after MUS surgery, many surgeons prefer indwelling bladder catheterization up 
to 1 week (3 to 7 days) and retesting the patient after catheter removal. There 
is, however, almost no consensus in the literature about the strategy to follow 
when the voiding trial 1 week after sling surgery fails. In cases of retention 
lasting longer than 1 week, some surgeons prefer an early surgical intervention 
to cut the tape, whereas some prefer to switch to clean intermittent 
catheterization as advocated by Elliott and Comiter (2012). However, there is a 
paradigm shift among surgeons toward earlier intervention because delayed 
time to urethrolysis and longstanding obstruction can lead to irreversible bladder 
dysfunction. 
 
Interference on female sexual function 
 
In the last few years an increasing number of studies have investigated 
the potential impact of MUS on women´s sexual health. Unfortunately, most are 
retrospective series that report mainly on dyspareunia as the sole sexual health 
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complication of these surgeries, ignoring the many areas of female sexual 
dysfunction. Sexual dysfunction (SD) is present in almost half of the women 
who complained of UI or recurrent/persistent LUT symptoms (Salonia et al, 
2006). On the other hand, cure of UI can solve some forms of SD, in particular, 
those associated with coital incontinence. 
Some studies report that dyspareunia is much more common after TO 
than RP MUS, in 18,5% of the women treated with a TO sling but only in 3.8% 
of women after RP MUS (Petri and Ashok, 2012). On the contrary, a report on 
the TVT-OTM (Ethicon, Sommerville, NJ, USA) procedure in women with SUI did 
not significantly affect sexual function, with more than half (54.5%) of the 
women reported an improvement in sexual function after surgery and 45.5% 
reported no change (Xu et al, 2011). Some authors report that sexual function 
(SF) scores improve after surgery for UI (Rogers et al, 2006).  
A recent meta-analysis exclusively addressing this matter has given 
important insights into this topic (Jha et al, 2012). Coital incontinence is 
significantly reduced following continence surgery. However, its impact on SF 
may be limited because at least half of all women undergoing surgery for SUI 
are likely to experience no change in SF. There is no difference in SF when 
comparing RP or TO mid-urethral slings.  
 
Post-operative pain 
 
A bothersome complication particularly associated with TO MUS 
procedures is postoperative leg pain. The etiology of the pain is hypothesized to 
be due to either subclinical hematoma or to a transient neuropathic 
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phenomenon (Dmochowsky et al, 2007). A recent review assessing the 
evidence on the complications of RP and TO procedures revealed groin or thigh 
pain to be significantly more common in the TO group (Moore et al, 2007). 
Neurologic adverse effects such as numbness or weakness in the legs or pelvic 
area were reported to be more common in the TO group of the TOMUS study 
(Brubaker et al, 2011). Laurikainen et al, in a RCT (2007), reported that groin 
pain was more frequent with the TO route (16% vs 1.5%). A recent Cochrane 
review also considers that the TO approach was associated with more groin 
pain (12% versus 1.7%, RR 6, 95% CI: 3-11) (Ogah et al, 2011). 
  
 Some authors (Deng et al, 2007 and Costantini et al, 2007) highlight the 
importance of voluntary reporting of MUS-related complications, such as that 
register made by the Food and Drug Administration (FDA) manufacturer and 
user facility device experience (MAUDE). These authors found a significant 
discrepancy between scientific reports and this MAUDE database, concerning 
major MUS-related complications, with up to 4 times as many major 
complications. These findings gave a false sense of security. Several 
explanations may be found: (1) reports may understate complications, (2) 
surgeons who have higher complication rates do not answer questionnaires, (3) 
differences exist between high- and low-volume surgeons, and (4) 
underreporting or over-reporting complication rates might be accounted for by 
surgeons who manage the complications. 
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SINGLE-INCISION VAGINAL SLINGS 
 
The increased number of incontinence procedures has prompted 
additional development of lesser invasive procedures aiming to further decrease 
morbidity and costs related to operating room resources, hospital stay, recovery 
time, pain and time to return to work. Indeed, a way to increase women’s 
adherence to surgical treatment of SUI is to opt for minimally invasive 
procedures. Around 2006 appeared the first reports on some new tension-free 
mid-urethral vaginal slings, known as single-incision vaginal slings (Neuman, 
2008; Petros and Richardson, 2005), which were introduced with the concept of 
a shorter tape, inserted through a single vaginal incision, providing a 
suburethral hammock, avoiding the blind passage of trocars through the 
retropubic space or the groin muscles as the previous methods required. The 
aim of these techniques was to provide an equally effective procedure to 
tension-free mid-urethral vaginal slings with synchronous reduction in morbidity. 
Data on these new single-incision slings (SIS) are mainly available in small 
cohorts, with very short follow-ups. Although results seem comparable to 
conventional MUS, these new slings need adequate prospective studies in 
order to adequately clarify their precise indications and utilization limits. These 
potential advantages, if proven, may be reflected in improving women’s quality 
of life (QoL) and potential cost savings to health providers and society. 
However, the advantages just cited would be only relevant if SIS are proven to 
have a similar clinical efficacy compared with traditional MUS. 
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TVT Secur™ 
 
The first widespread SIS to be introduced was TVT-Secur™ in 2006 
(Gynecare, Ethicon, Sommerville, NJ, USA). This sling consists of a short 
(1,1x8 cm) laser cut tape of the same material as TVT™. Specially designed 
extremities are coated with a fleece of absorbable materials (Vycril™ and 
PDS™). The latter exerts a velcro effect on host tissues, offering immediate 
fixation and providing a pull-out force similar to TVT™ (Rezapour et al, 2007). 
The tape comes attached to a steel blade-shaped inserter in each tip, which is 
released by pulling a metal trigger and gently twisting the inserter. As neither 
sutures nor inserting needles are necessary for the sling placement, the risks of 
internal injuries inherent to the blind passage of inserting needles are 
hypothetically minimized. The system can be fixed in a U-shaped position, 
resembling the retropubic approach (vertical) or in a hammock (H) position 
(lateral), resembling the TVT-OTM route (TVT Secur information manual, 2007). 
As the theoretical advantage of TVT-Secur™ is minimizing complications, 
surgeons usually do not consider the alternative “U” position, as this position is 
more susceptible of injuring abdominal viscera, in particular the bladder.  
One issue about TVT-Secur™ is the learning curve. Neuman, in an initial 
series of 100 patients, after dividing the cohort into the first 50 and last 50 
patients, found that success rate at 1 month follow-up was 80% in the former 
and 92% in the latter group (Neuman, 2008). Vaginal perforation was 8% and 
0% and mesh extrusion was 12% and 8% in the first and second fifty patients, 
respectively. Unintended tape removal occurred in 5 patients in the first group 
and in none in the second. These findings clearly indicate that surgeons must 
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master the technique in order to optimize results. Points of technique requiring 
surgeon expertise include the depth of submucosal dissection, the width of the 
insertion tunnel, a meticulously detachment of the inserter and the adjustment 
of the sling placement, ideally left abutting the urethra. 
Meschia et al (2009) prospectively reported on 95 patients treated in 4 
Italian centers. After an average follow-up of 15 months subjective cure rate 
was 78% and objective cure rate 81%. Complications referred were 2 
inadvertent removal of tapes during blade inserter disassembly, requiring the 
placement of a new device. Bleeding over 500 cc occurred in 2 patients and 
one patient had transient VD which resolved spontaneously.  
 Taken together, these results indicate that TVT-Secur™ may be effective 
in the cure of SUI. Morbidity seemed lesser than in classical slings. None of the 
series reported bowel, bladder or urethral injuries and groin pain appears to be 
slightly lower than that after standard slings. The long-term outcome of TVT-
Secur™ is unknown. Optimization of the results is highly dependent on proper 
training and attention to technique details, which may require an unexpected 
long learning curve.  
 
Mini Arc™ 
 
Mini-Arc™ (American Medical Systems, Minnetonka, MN, USA) design is 
very simple. A small elastic 8 cm long polypropylene mesh is attached to two 
small harpoon-like anchoring extremities. These are easily directed through the 
para-urethral tissues with a curved metallic handle (2.3mm needle) docked in 
the anchors.  
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Gauruder-Burmester and Popken (2009) used Mini-Arc™ in a total of 97 
women with mixed or stress urinary incontinence (SUI). The Mini-Arc™ sling 
was the initial intervention in 37 (38.2%) patients and the second intervention in 
60 (61.7%) patients with recurrent incontinence. Six weeks after the sling 
procedure the cough stress test was negative in 83.1% of the women. This 
number decreased slightly at 12 months, when 77.8% of the women were 
cured. De novo urgency occurred in 32 women (36.8%). Quality of life was 
significantly improved at 12-month follow-up in 69.1% of the patients (p<0.001). 
The number of pads decreased significantly, from 2.2 to 0.6 (p<0.001) after the 
procedure. One hematoma and one bladder perforation were reported as 
complications. 
A study conducted in a single centre in the United States, with 61 
patients, evaluated retrospectively at 12 months, reported overall cure rates of 
91%, determined by the both physician and patient (Moore et al, 2009). There 
were no intra-operative complications and the only post-operative adverse 
event was a case of urinary retention requiring sling loosening. 
These initial, albeit non-comparative studies, indicate that Mini-Arc™ is 
safe and easily reproducible, with a short learning curve. Cure rates at a short 
follow-up are high, in the range of those reported by series using conventional 
slings. 
  
Tissue Fixation System 
 
The Tissue Fixation System (TFSTM) (TFS Manufacturing PTY LTD, 18 
Kincaid Avenue, North Plympton, SA, Australia) consists of an adjustable 
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polypropylene mesh that uses two small plastic anchors to fix it into the inferior 
surface of the pelvic muscles and tissues below the retropubic space, in an 
hammock-like tension-free position. 
This SIS was developed by Petros and their report at medium follow-up 
(3 years) provides data about 36 patients with SUI (Petros and Richardson, 
2008). Data were collected by a telephone interview conducted by a nurse and 
a negative answer to the question “Do you leak when you cough?” was 
considered as a cure. Cure rates on 31 eligible patients were of 80%. 
Complication rates are not described. 
Another report on TFSTM (Sekiguchi et al, 2009), describes a prospective 
study on 44 women with urodynamic SUI. This cohort had a high percentage of 
women with poor sphincteric function (34,1%). With a mean follow-up of 16,1 
months, success was noted in 91% of patients, with 4 cases considered 
treatment failures (9%). Pain described at discharge was minimal. No significant 
blood loss was described. Five patients (11%) had transient voiding difficulties 
that resolved after 48 hours of indwelling catheterization. Nine patients (20%) 
had occasional urge incontinence in the post-operative follow-up, that resolved 
spontaneously or with pelvic floor exercises. 
 These studies, although including a low number of patients, provide an 
insight into the results of this SIS, that seem comparable to conventional MUS 
in terms of success rates, with a small cohort followed at medium-term. 
Morbidity seems also in accordance with the expected minimally invasiveness 
of this sling. However, data are scarce and it is not possible to draw convincing 
conclusions.  
This device is not commercially available in Portugal. 
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Other single-incision slings 
 
These other SIS are evaluated separately because they have a very low 
number of patients, very limited follow-up or the results are not comparable with 
the aforementioned SIS.  
Arcus to arcus (Palma et al, 2008), a transobturator route SIS, has been 
used in 20 patients, with a 12 month´s follow-up cure rate of 88%. 
Contasure NeedlelessTM (Neomedic International SL, Barcelona, Spain) 
although being placed through a vaginal single-incision, is somewhat different in 
terms of invasiveness, as it requires the introduction of a surgical forceps into 
the urogenital diaphragm, and then it is opened to deploy the mesh into the 
internal obturator muscle. Preliminary data (Navazo et al, 2009) on 120 patients 
evaluated retrospectively, with 24 months follow-up, show 84% cure and 8% 
improvement rates, with low and mild morbidity profile. The authors state by 
themselves that this is not a mini-sling, because it is a 114mm long mesh, with 
138% more surface area. 
Serels et al (2010) reported on preliminary results of Solyx® (Boston 
Scientific Corporation, Natick, MA, USA), a self-anchoring sling system. This 
retrospective study on 63 patients, with only 6.5 months follow-up, shows 95% 
dry rate and 2 cases of transient voiding dysfunction as the sole morbidity. This 
SIS design resembles, in some aspects, Mini-ArcTM 
MinitapeTM (GyneIdeas, Glasgow, UK) is a 14 cm long mesh with terminal 
anchors that fixate the tape in the RP space. It was evaluated in an adequately 
designed multicentre prospective trial, with 24 months mature follow-up (North 
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et al, 2010). However, results were disappointing, with only 33% and 10% of 
patients cured at 1 months and 24 months, respectively (n=60). 
 
Current perspective 
 
As discussed before, treatment of female SUI is at a point where a 
myriad of new devices are being designed and launched into medical practice 
without adequate clinical evaluation. These innovative surgical procedures are 
introduced in the market without any specific regulatory framework (Costantini 
and Lazzeri, 2010). That is the opposite of what happens with a new drug, 
which is assessed through specific clinical research phases, well characterized 
and regulated in the vast majority of countries. The Lancet has published a 
paper on this particular matter (Barkun et al, 2009), with the grant of official 
health authorities, proposing a staged surgical model with 4 phases, resembling 
the drug development stages in human beings. This paper has also been 
entitled as the Balliol Colloquia achievements, and surgeons with interest in UI 
should put adequate emphasis on safety and efficacy of standard treatments, 
introducing adequate stage research practices into the operating theatre. Only 
then, surgical innovations can be promptly considered on academic urology 
institutions, which will support surgical development under rigorous guidelines 
and encourage early registration of new procedures in public registries 
(Costantini and Lazzeri, 2010). 
It is obvious from the previous descriptions that SIS are not equal to each 
other, although their potential advantages, if proven, may be reflected in 
improving women’s quality of life and potential cost savings to health providers 
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and society. Hence, clinical trials are necessary to define which SIS will meet 
the required criteria of efficacy and safety, in order to be included in the 
armamentarium of surgical therapies for SUI. 
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OBJECTIVES 
 
Prospective enrollment of patients submitted to single-incision vaginal 
sling placement as the initial surgical treatment of SUI, in order to evaluate 
short-term success rates, post-operative complications and quality-of-life 
outcomes. 
 
Evaluate both available single-incision slings, TVT-SecurTM and Mini-
ArcTM. 
 
Long-term follow-up of the initial population. 
 
Randomized clinical trial comparing SIS with the gold-standard mid-
urethral sling. 
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symptoms, incontinence cure rate and the 
King’s Health Questionnaire (KHQ) score 
were evaluated.
 
RESULTS
 
The operative duration was 12 min; the 
mean pain score was 2.3 and only one 
patient had transient voiding difficulties. 
After a mean follow-up of 15 months, 71% 
of the patients were dry and 14% improved. 
The KHQ scores decreased significantly for 
most subscores. Urgency appeared 
 
de novo
 
 
in six patients (5.6%), and vaginal erosion 
required one TVT-Secur explantation.
 
CONCLUSION
 
This study shows that TVT-Secur is a simple 
and safe treatment for female SUI, but 
before recommending this sling as a first 
choice for treating SUI, TVT-Secur must pass 
the test of time and comparative studies 
with conventional slings.
KEYWORDS
 
female stress urinary incontinence, mid-
urethral sling, suburethral tape, TVT, mini-
sling, TVT-Secur
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OBJECTIVE
 
To evaluate the short-term surgical 
complications and results of a tension-free 
vaginal tape (TVT) system (TVT-Secur
 
TM
 
, 
Gynecare, Ethicon, Somerville, NJ, USA) in 
the treatment of female stress urinary 
incontinence (SUI).
 
PATIENTS AND METHODS
 
TVT-Secur was applied to 107 women with 
SUI through a vaginal incision and left 
abutting the urethra. Postoperative pain, 
complications, de novo lower urinary tract 
 
INTRODUCTION
 
Recent epidemiological studies estimate that 
stress urinary incontinence (SUI) affects 40% 
of the women in the Western world [1]. 
At present one of the most successful 
treatments for SUI is provided by surgery [2], 
but unfortunately, too few women are 
receiving appropriate surgery for SUI [1]. One 
way to increase the adoption of surgery for 
SUI by these women is to opt for minimally 
invasive procedures. This was why Burch 
colposuspension, once the standard 
technique [2], was progressively discarded in 
favour of tension-free vaginal tape (TVT), the 
first mid-urethral sling to be introduced into 
clinical practice in 1996, by Ulmsten 
 
et al.
 
 [3]. 
When both procedures were compared by 
appropriate randomized clinical trials it 
became clear that the advantage of TVT 
did not lie in the success rate. At 5 years 
of follow up, 69% of women after Burch 
colposuspension and 75% after TVT 
were cured [4]. However, while Burch 
colposuspension had a median hospital stay 
of 5 days and a median time to return to work 
of 10 weeks, TVT required only 1 day and 
4 weeks, respectively [5].
While being considered a highly successful 
[6], minimally invasive technique, TVT is not 
devoid of serious complications, in general 
associated with the ‘blind’ course of the 
needles through the retropubic space. A high 
rate of bladder perforation and occasional 
severe vascular and bowel injuries have been 
reported, in a few instances leading to the 
patient’s death [7–9]. In an attempt to 
obviate the needle passage through the 
retropubic space, transobturator slings were 
introduced. Nevertheless, transobturator 
tapes have been associated with prolonged 
postoperative pain referred to the groin 
and upper thigh, after obturator nerve 
entrapment by the mesh, in many patients 
[10]. In addition, vascular injuries and 
perineal fasciitis have also been reported, 
associated with the death of two patients 
[11]. Thus, further improvement in mid-
urethral slings is still possible.
The novel TVT-Secur
 
TM
 
 (Gynecare, Ethicon, 
Sommerville, NJ, USA) mid-urethral sling is an 
8-cm long laser-cut polypropylene mesh that 
is put in place through a single vaginal 
incision. Specially designed absorbable ends 
offer immediate fixation of the mesh to the 
obturator internus internal fascia. As neither 
sutures nor inserting needles are necessary 
for placing the sling the risks of internal 
injuries inherent to the blind passage of 
inserting needles are hypothetically 
minimized. Here we report the surgical 
complications and short-term results with 
this device. Preliminary data were presented 
in abstract form previously [12].
 
PATIENTS AND METHODS
 
In a prospective study, 107 women referred to 
our department for SUI or mixed UI associated 
with urethral hypermobility were treated with 
BJUI
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the TVT-Secur. Written informed consent was 
obtained from every patient. Patients with 
previous surgical procedures for SUI, genital 
prolapse Stage 2 or higher (by the Pelvic 
Organ Prolapse Quantification system) in any 
vaginal compartment or obesity (body mass 
index 
 
>
 
30 kg/m
 
2
 
) were excluded. The 
preoperative evaluation consisted of a 
medical history and physical examination 
with neurological and urogynaecological 
assessment. All patients had a stress test with 
the bladder previously filled to 300 mL and a 
quality-of-life assessment questionnaire 
(King’s Health Questionnaire, KHQ). All 
patients complaining of urgency, frequency or 
nocturia besides SUI had a urodynamic 
evaluation to exclude detrusor overactivity.
The surgery was done by one or more of the 
authors; the slings were placed according to 
the technique described by Neuman [13], and 
always placed in the hammock position. As 
the theoretical advantage of TVT-Secur is 
minimizing complications, we did not 
consider the alternative ‘U’ position, as this is 
more susceptible to injuring abdominal 
viscera, in particular the bladder [13]. The 
procedure was carried out with the patient in 
the lithotomy position, with the hips flexed at 
90
 
°
 
. A 16 F Foley catheter was introduced into 
the bladder and urine evacuated. A 1–1.5-cm 
vaginal incision was made in the midline, 
1 cm posterior to the external urethral 
meatus. Sharp para-urethral dissection using 
Metzenbaum scissors was extended laterally 
until the tip of the scissors touched the 
inferior border of the ischiopubic ramus. Care 
was taken to avoid any dissection in the area 
of the obturator foramen or perforation of the 
internal obturator fascia. The TVT-Secur, 
mounted on the inserter handle system, was 
then advanced through the trajectories 
created. Then, with the TVT-Secur handle 
firmly grasped on a needle-holder, the device 
was pushed just behind the ischiopubic 
ramus to place its extremity in the fibrous 
attachment of the obturator internus muscle. 
Usually this procedure was initiated on the 
right side of the patient and was then 
repeated on the left side. The position of the 
TVT-Secur was then checked immediately, to 
confirm that the mesh was abutting the 
urethra and to exclude vaginal perforations, in 
particular in the vaginal cul-de-sac. The right 
inserter handle was then detached from the 
mesh by pulling out the release wire and 
twisting the handle, while gently pushing 
it into the patient’s body. The left handle 
was then disconnected from the mesh as 
previously described for the right side. Again, 
while twisting the handle to disassemble it 
from the mesh, a gentle pressure was put to 
maintain the tip of the sling in the correct 
position. Maintaining a pushing force in the 
sling while disassembling the handles is 
essential to leave the mesh in close contact 
with the peri-urethral tissues, which could 
eventually be seen protruding from the 
orifices of the polypropylene mesh. The final 
tension of the TVT-Secur was therefore 
identical in every patient, as we did not use an 
intraoperative stress test to adjust the sling. 
We feel that the information given by such a 
test in a patient recovering from general 
anaesthesia is unreliable. The procedure was 
concluded with the closure of the vaginal 
incision with a 3–0 polyglactin (Vicryl Rapide, 
Johnson & Johnson Intl., Brussels, Belgium) 
running suture and a vaginal packing with 
lubricated gauze.
Postoperative analgesia consisted of 
paracetamol (1 g orally twice daily) and 
ibuprofen (400 mg, orally twice daily). The 
Foley catheter and the vaginal gauze were 
removed on the day after surgery and the 
postvoid residual urine volume (PVR) was 
measured by ultrasonography; if the PVR was 
 
<
 
100 mL the patient was discharged on 
prophylactic antibiotics and conventional 
analgesic treatment (paracetamol, 1 g, orally, 
8/8 h). At discharge patients were asked to 
rate the pain felt in the first 24 h, using a 
visual analogue scale of 1–10.
Patients were re-assessed by the first author 
at 1, 6 and 12 months after surgery. For the 
purpose of the present analysis there was an 
extra follow-up in July 2008, so the follow-up 
reported refers to this last assessment. The 
presence of pain and LUTS, including urine 
leakage, was elicited at each visit. In addition, 
patients repeated a cough and Valsalva stress 
test with the bladder previously filled to 
300 mL (considered positive when there 
was urine leakage) and the KHQ at 1 and 
6 months. Treatment was considered 
successful if the patient ceased to wear 
continence pads and reported no episodes of 
UI, and the stress test was negative (patient 
cured) or if there was at least a 
 
≥
 
50% 
decrease in daily pad use, and the patient 
answered ‘yes’ to the question: ‘are you 
satisfied with the result of the surgery?’ 
(patient improved). All other situations were 
considered as treatment failures. Student’s 
 
t
 
-
test was used for the statistical analysis, with 
 
P
 
 
 
<
 
 0.05 considered to indicate significance.
 
RESULTS
 
The patients had a mean age of 55 years and 
a mean parity of two; 91 (85%) had pure SUI 
and 16 (15%) had mixed UI with predominant 
SUI symptoms. None of the latter patients had 
detrusor overactivity. The mean operative 
duration was 12 min; the surgery was 
performed under sedation (62 patients, 58%) 
or spinal anaesthesia (45, 42%). There were no 
cases of bowel injury, bladder perforation, 
haematuria, excessive bleeding or haematoma 
formation.
All patients voided spontaneously and all 
but one had a PVR of 
 
<
 
100 mL. One patient, 
with a PVR of 300 mL, was discharged with 
permanent bladder drainage. One week later, 
at a new voiding trial, the PVR was already 
 
<
 
100 mL and the urethral catheter was 
removed. The mean (median) pain intensity 
during the first 24 h was 2.3 (2) and usually 
referred to the vagina. There were no 
complaints of numbness or pain in the thighs 
or groin. During the follow-up, one patient 
was detected to have a major vaginal erosion 
that dictated removal of the mesh. This was 
done through an anterior vaginal incision, 
similar to the one used for sling placement. 
The mesh was easily identified at the midline, 
loosened 3 cm to each side and, because there 
was no evidence of infection, simply cut and 
removed. Another five patients had minor 
erosions (
 
<
 
5 mm) that were successfully 
treated with the application of topical 
oestrogens. Mild 
 
de novo
 
 urgency appeared 
in six patients (5.6%), which was easily 
controlled with appropriate anticholinergic 
therapy.
One patient never appeared at the follow-up 
visits, so data are available for 106 women. 
The mean (median, range) follow-up was 
15 (14, 11–22) months. At the last assessment 
75 patients (71%) were cured and 15 (14%) 
were improved, corresponding to an overall 
success rate of 85%, with the procedure 
failing in 16 (15%).
The KHQ scores before and after surgery were 
available for 68 women; this group were 
demographically similar to that of the whole 
sample, with a mean age of 57 years and a 
mean parity of 1.8. The cure rate was 69% (47 
patients) and the improvement rate 18% (12 
patients), making a success rate equivalent to 
that of the all patients. At 6 months after 
surgery there was a significant reduction in 
the KHQ scores, in both the groups designated 
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cured and improved. Figure 1 shows the 
partial scores for these two groups, at 
baseline and at 6 months after surgery.
 
DISCUSSION
 
The ideal mid-urethral sling should be simple 
to place, require a short hospital stay, cause 
rare and mild complications, provide a rapid 
return to active life, be reproducible and give 
a high success rate. The present study 
evaluating the short-term results of TVT-
Secur seems to confirm that this ‘mini-sling’ 
might fulfil these criteria.
The procedure is simple, requiring a single 1-
cm incision in the anterior vaginal wall, and 
the extension of the dissection required to 
create a passage for introducing the sling is 
very limited. There were no cases of bladder 
perforation, bowel injury or blood vessel 
injury leading to severe bleeding or large 
haematoma formation. Complications as a 
whole were less than those reported for 
retropubic or transobturator slings; the 
reported bladder perforation rates associated 
with TVT are 0.7–6.5% [10,14,15]. For 
transobturator tapes, although generally 
believed to be exempt from such a hazard, can 
be associated with bladder perforation [16]. 
The pain reported by patients was mild and 
easily controlled using common analgesics. 
Persistent groin pain or severe, eventually 
lethal complications, associated with 
retropubic or transobturator slings, are not 
reported from large series [15,17], but they 
have occurred with both procedures. In all, 38 
cases of bowel perforation were reported to 
the USA Food and Drug Administration/
Manufacturer and User Facility Device 
Experience Database, all related to retropubic 
slings, causing six deaths in all [8]. Thirty-six 
vascular injuries were reported after 
retropubic (33 cases) and transobturator 
slings (three cases), responsible for three 
deaths [8].
The total operative time necessary for placing 
a TVT-Secur was 12 min, which compares 
favourably with times reported for TVT and 
Monarc
 
TM
 
 (American Medical Systems, 
Minnetonka, MI, USA) slings in the TORP 
study, at 18.5 min and 14.6 min, respectively 
[14]. Although cystoscopy was not used 
systematically in the present study during 
surgery, there is a report of bladder injury 
during TVT-Secur placement [18]. Thus, 
cystoscopy might be recommended at the end 
of the procedure, especially when surgeons 
are gaining experience with the technique.
The hospital stay was 1 day; in our centre 
such a duration was dictated by the process 
of reimbursement of our local health system, 
that obligates a minimum hospital stay of 
24 h. However, we believe that this procedure 
can easily be done as an ambulatory 
procedure. In addition, we only had one case 
of transient urinary retention (1%) while 
for retropubic slings the reported rates are 
4–17% [14,15] and for transobturator tapes 
2.6–11% [10,15].
The reproducibility of a surgical procedure 
designed to treat female SUI is essential to 
guarantee the success of the operation 
worldwide. The technique for placing the TVT-
Secur is easily and rapidly learned by the 
average surgeon qualified to treat SUI. 
However, caution is required when placing the 
TVT-Secur absorbable extremities in the 
fibrous attachment of the internal obturator 
muscle, as this might not be quickly achieved 
by inexperienced surgeons [19]. Another 
important point in the surgery is the 
disconnection of the inserter from the mesh. 
This entails a gentle twist of the handle while 
gently pushing the device into the patient’s 
body. This maintains the ideal tension of the 
mesh which should be left abutting the 
urethra, forcing the peri-urethral tissues to 
protrude slightly through the mesh orifices. 
This is radically different from what has been 
taught to surgeons about retropubic or 
transobturator sling placement. In these cases 
the mesh must be left tension-free, with 
2–3 mm between the mesh and the urethra. A 
recent study showed that the accumulation of 
experience affects the success rate with TVT-
Secur [13] and thus surgeons should refrain 
from attempting this surgery before receiving 
adequate training.
In the present study we used patient-reported 
symptoms and a stress test to define cure. 
These variables are commonly used to define 
cure after surgical treatment for SUI [20,21]. 
Although theoretically more objective for 
measuring incontinence, pad tests were 
shown to lack reproducibility between 
consecutive examinations [22]. Moreover, 
there is no direct correlation between this 
objective measure and subjective measures of 
improvement [22]. The success rate of TVT-
Secur in the present study, at a mean follow-
up of 15 months, was 85%; other recent 
short-term reports on TVT-Secur give success 
rates of 
 
≈
 
90% [13,23,24]. The success rates 
offered by TVT-Secur are therefore similar to 
those offered by other procedures also at a 
short follow-up. At 3 months the TORP study 
reported objective cure rates of 79.3% and 
84.5% for retropubic and transobtutator 
slings, respectively [14]. Porena 
 
et al.
 
 [15] 
reported a rate of ‘dry’ or ‘improved’ patients 
with a 31-month follow-up at 90% for both 
retropubic or transobturator sling. Only 
Laurikainen 
 
et al.
 
 [10] obtained objective cure 
rates greater than those cited here; at the 2-
month follow-up the cure rates were 98.5% 
for the retropubic and 95.4% for the 
transobturator sling. The important values are 
 
FIG. 1. 
 
The KHQ scores of the cured (47) and improved (12) patients, before and at 6 months after placing the 
TVT-Secur; 
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those that reflect the cure rates at 
 
≥
 
5 years 
of follow-up, and these are still lacking for 
TVT-Secur.
In conclusion, this initial report on the use of 
TVT-Secur for treating women with 
predominantly SUI shows that the technique 
is simple and free from severe complications. 
As long as the surgical steps are followed 
strictly during the operation, a high success 
rate can be expected, although the 
reproducibility of this technique might 
require adequate training [19]. Furthermore, 
studies are needed to establish the long-term 
results of the procedure.
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RESULTS
 
• Cure rate was 80% and improvement rate 
was 11%. Pain intensity was minimal on a 
visual analogue scale and transient urinary 
retention occurred in three patients, one 
requiring sling section.
•
 
De novo
 
 urgency was reported by 6% of 
women. Severe incontinence was less likely 
to be cured: 70% if 
 
>
 
5 pads per day (ppd); 
94% if 
 
<
 
2ppd; 94% if 2–4ppd, 
 
P
 
 
 
<
 
 0.05).
• There was no difference in success rates 
between the ﬁrst 50 and the last 50 patients. 
BMI, ISD and age also did not inﬂuence 
success rate.
 
CONCLUSION
 
• Mini-Arc
 
TM
 
 attained high success rates 
at 1 year follow-up. The procedure was 
easy to learn and was associated with 
very low and mild morbidity. Severe 
incontinence was identiﬁed as a risk 
factor for failure.
 
KEYWORDS
 
female stress urinary incontinence, mid-
urethral sling, suburethral tape, Mini-Arc, 
mini-sling, single incision sling
Study Type – Therapy (case series)
Level of Evidence 4
 
What's known on the subject? and What does the study add?
 
Single-incision slings (SIS), requiring very limited intracorporeal dissection, have been 
recently introduced on the premise that they might increase safety of female stress 
urinary incontinence treatment. However, their success rate has been insufﬁciently 
evaluated.
This is a large prospective series on Mini-Arc SIS, with data on 105 patients available at a 
mean follow-up of 12 months. Success rates are comparable while morbidity was lower 
and milder than that associated retropubic or transobturator slings. This study warrants 
a large-scale randomized comparative study between Mini-Arc and standard mid-urethral 
tapes, matured at longer follow-up time.
 
OBJECTIVE
 
• To investigate the success and 
complication rates for Mini-Arc
 
TM
 
 single 
incision sling in the treatment of female 
stress urinary incontinence (SUI).
 
MATERIALS AND METHODS
 
• A total of 119 female patients with 
pure SUI were enrolled in a prospective 
study. From these, 105 were available 
with a minimum follow-up of 6 months 
and a mean follow-up of 12 months.
• Success, as determined by patient-
reported outcomes, and complication 
rates, as well as impact of learning 
curve, body mass index (BMI), 
intrinsic sphincter deﬁciency (ISD), 
incontinence severity and age were 
investigated.
 
INTRODUCTION
 
Female stress urinary incontinence (SUI) is the 
most common form of incontinence in the 
western world. It reduces quality of life, 
causes important social limitations and 
represents an important economic burden [1]. 
Pelvic ﬂoor muscle training can improve 
continence, particularly in younger patients 
with mild forms of the disease [2]. Prolonged 
physical exercise associated with weight 
reduction may achieve cure rates of up to 
25% [3]. However, the success of conservative 
treatments is highly dependent on a patient’s 
persistence with therapy. Therefore, for most 
women, surgery remains the mainstay of SUI 
treatment. Simpliﬁcation of the surgical 
technique, aimed at reducing morbidity while 
maintaining a high cure rate, has been a 
natural evolution, therefore increasing 
women’s adherence to treatment. Retropubic 
(RP) [4] and transobturator (TO) [5] slings 
replaced worldwide the previously considered 
standard procedure, Burch colposuspension 
[6]. In spite of the excellent success rates 
achieved with RP and TO tapes, shorter, 
single-incision slings were designed to further 
minimize surgical morbidity. TVT-Secur
 
TM
 
 
(Gynecare, Ethicon, Sommerville, NJ, USA), the 
ﬁrst single-incision sling, was launched in 
2006 and paved the way [7–10], with only 
four reports of bladder injury [10,11] and two 
cases of major bleeding [9,12], in almost 1000 
patients treated. No cases of urethral or bowel 
injuries and persistent groin pain were 
referred and no deaths occurred [7–11]. This 
BJUI
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low morbidity compares favourably with that 
reported for RP and TO slings [13,14]. 
However, TVT-Secur
 
TM
 
 cure rates at mid-term 
appear to be lower than those after standard 
slings [15], eventually related to the technical 
complexity of the procedure [7,16].
The second single-incision sling to be 
introduced worldwide was the Mini-Arc
 
TM
 
 
(American Medical Systems, Minnetonka, MN, 
USA). It is an 8.5cm long monofilament 
macroporous type 1 polypropylene mesh, 
with integrated anchor-like self-fixating 
extremities, and was introduced in 2007. 
Initial experience was promising with little 
morbidity and success rates in the short-term 
are comparable with the conventional RP or 
TO slings [17,18].
In this paper we present our experience with 
Mini-Arc
 
TM
 
, as a short-term prospective 
evaluation, analysing success rates and 
complications. In addition we investigated the 
influence of incontinence severity, body mass 
index (BMI), intrinsic sphincter deficiency 
(ISD), age and learning curve on success rate. 
Previous data have been presented in abstract 
form [19].
 
MATERIALS AND METHODS
 
A total of 119 consecutive women from our 
surgical waiting list, with pure SUI, were 
prospectively enrolled in this study. 
Preoperative evaluation included a medical 
history focused on urogynaecological and 
neurological assessments. All patients were 
submitted to preoperative cystometry, 
uroflowmetry and Valsalva leak point pressure 
(VLPP) measurements. In all cases, SUI was 
shown urodynamically. Women with previous 
surgeries for SUI, genital prolapse Grade 
2 or higher (by the Pelvic Organ Prolapse 
Quantification System), complaints of 
urgency, frequency, nocturia or demonstration 
of detrusor overactivity were excluded. 
Terminology used in this manuscript is defined 
by the ICS Standardization Sub-committee 
[20]. Written informed consent was obtained 
from every patient. Preoperative impact of SUI 
on quality of life was assessed using the King’s 
Health Questionnaire (KHQ) Score [21].
All surgeries were carried out with the patient 
in the lithotomy position, with hips flexed at 
90 degrees. Intravenous sedation was the 
preferred type of anaesthesia (71 patients, 
68%) and spinal anaesthesia was used in the 
remainder (34 patients). Preoperative 
antibiotic prophylaxis consisted of a single 
injection of ceftriaxone. The bladder was 
evacuated through a 16Fr catheter. A 1.5-cm 
anterior vaginal wall incision was performed, 
1cm posterior to the urethral meatus. Sharp 
para-urethral dissection was carried on 
laterally, until the scissors reached the pubic 
rami. The direction of needle introduction was 
towards the point where the medial border of 
the adductor longus tendon and the inferior 
pubic ramus met, as determined by palpation. 
The tip of the needle passer was then keyed 
to the sling extremity, so that the mesh lay on 
the convexity of the passer. Slight tensioning 
of the mesh with the index finger was shown 
to be helpful. The procedure was performed 
first on the right side of the patient. The 
sling was advanced through the created 
trajectories and was then pushed along the 
posterior surface of the ischio-pubic ramus, 
until the midline mark on the mesh was 
underlying the urethra. Care was taken not to 
perforate the obturator membrane, as the 
hook-shaped extremity should lie fixed in the 
obturator internus muscle and fascia. The 
procedure was then repeated on the left side, 
making sure that the mesh was not twisted, 
and the needle introducer was disengaged as 
soon as a tension-free positioning under the 
urethra was achieved. Vaginal perforation was 
ruled out on either side. We did not use the 
redocking procedure as described by the 
manufacturer because we did not perform 
any intraoperative stress test to assess sling 
tensioning. The surgical wound was then 
closed with a 3-0 polyglactin (Vicryl Rapide, 
Johnson & Johnson Intl., Brussels, Belgium) 
running suture and a vaginal gauze was 
positioned. The bladder catheter was left in 
place.
Postoperative analgesia, comprising 
paracetamol (1g, orally, three times daily) 
and ibuprofen (400mg, orally, three times 
daily). On postoperative day 1, the vaginal 
gauze and the Foley catheter were removed 
and postvoid residual urine volume was 
measured after spontaneous voiding. If 
estimated to be below 100mL, patients were 
discharged on conventional analgesics 
(paracetamol, 1g, orally, three times daily). At 
discharge, women were asked to rate the pain 
felt in the first 24 hours through a 0–10 visual 
analogue scale.
Routine postoperative assessment of these 
patients comprised visits at 1, 6 and 12 
months after the procedure. Fourteen 
patients who presented at the 1-month 
postoperative visit did not respond to the 
other appointments; 13 of these patients 
were considered cured at that visit and one 
had a major acute neurological disability so 
lower urinary tract symptoms could not be 
assessed. Therefore data from the 6-month 
visit, where KHQ and uroflowmetry were re-
evaluated, were available from 105 patients. 
In addition, patients with a follow-up over 6 
months were invited for another evaluation to 
access their lower urinary tract symptoms, 
including urine leakage, pain and 
complications. In all, 71 patients had a follow-
up between 12 and 21 months. The total mean 
follow-up of the cohort at the present report 
is therefore 12 months.
Patients were considered cured only if 
they did not report any episodes of urine 
leakage and ceased to wear any protection 
for incontinence. If a patient reported 
persistence of urine leakage or maintained 
the use of incontinence protection but the 
number of pads used decreased by 
 
>
 
50% 
and if they answered affirmatively to the 
question ‘are you satisfied with the result 
of the surgery?’, then she was considered 
improved. All other cases were reported as 
failures.
The BMI was determined using WHO 
definitions [22]. It was considered that ISD 
was present if a VLPP 
 
<
 
60mmH
 
2
 
O was found 
[23]. The VLPP was determined by the 
measurement of intravesical pressure in the 
lithotomy position, at the volume at which 
patients reported a normal desire to void. 
Urodynamic evaluations were performed 
according to the criteria established by the 
ICS [24]. Incontinence was stratified by 
number of pads per day (ppd) in three groups 
according to severity: 
 
<
 
2; 2–4; 
 
≥
 
5. 
Preoperative and postoperative free 
maximum flow rate (Q
 
max
 
) and KHQ score were 
compared using a matched Student’s 
 
t
 
 test. 
Age, ppd, BMI and VLPP were associated with 
success rates using chi-squared (with Yates 
correction for continuity, if applicable) for the 
univariate analysis. Success rates of the first 
and last 50 cases were also compared. 
Statistical analysis was performed using SPSS 
version 17.0 (SPSS Inc., Chicago, IL, USA) and 
 
P
 
<
 
0.05 was considered significant.
 
RESULTS
 
Patients had a mean 
 
±
 
 SD age of 52 
 
±
 
 11.1 
years, mean BMI was 28.6 
 
±
 
 4.9kg/m
 
2
 
 with 73 
44
 
O L I V E I R A  
 
E T  A L .
 
©
 
 
 
2 0 11  T H E  A U T H O R S
 
1 6 1 8
 
B J U  I N T E R N A T I O N A L  
 
©
 
 2 0 11  B J U  I N T E R N A T I O N A L
 
patients 
 
<
 
30 and 32 patients with BMI 
 
≥
 
30; 
mean parity was 2.2 
 
±
 
 1.5. Mean pad usage 
was 2.8 
 
±
 
 2.0ppd with 16, 79 and 10 patients 
using 
 
<
 
2, 2–4 or 
 
≥
 
5 ppd, respectively. Mean 
duration of SUI was 7.4 
 
±
 
 6.3 years. Mean 
VLPP was 101.5 
 
±
 
 33.5cmH
 
2
 
O, with 14 
patients having VLPP
 
<
 
60cm H
 
2
 
O (13%). 
Preoperative mean maximum flow rate was 
27.0 
 
±
 
 8.7mL/s.
There were no cases of bowel injury, bladder 
perforation, haematuria, vaginal wall 
laceration, major bleeding or clinical 
haematoma formation. The mean pain score 
in the first 24h was 1.0 
 
±
 
 1.4. One patient had 
prolonged pain referred to the right groin that 
slowly waned over the initial 6 months. Two 
patients (2%) with an estimated postvoid 
residual urine volume 
 
>
 
100mL on the day of 
discharge and one (1%) not able to void 
spontaneously were discharged with an 
indwelling catheter. One week later, a voiding 
trial was repeated. The first two patients had a 
postvoid residual urine volume 
 
<
 
100mL, so 
the catheter was removed. The third 
maintained the incapacity to void and was 
therefore offered a midline sling section. Four 
patients (3%) reported the appearance of mild 
dyspareunia after the procedure, which was 
managed with lubricating cream until 
spontaneous resolution. Two patients (2%) 
had 
 
minor
 
 (
 
<
 
1cm) vaginal mesh exposure 
that was successfully treated with sexual 
abstinence and topical oestrogen application. 
Mild 
 
de novo
 
 storage symptoms (urgency, 
frequency, nocturia) were referred by seven 
patients (6%), but resolved spontaneously 
over time or were easily controlled with 
anticholinergic therapy.
With a mean follow-up of 12.4 months 
(range: 7–21 months), 84 patients were cured 
(80%) and 12 were improved (11%), 
amounting to a global success rate of 91%. 
Success rate in patients using 
 
>
 
5ppd at 
baseline was 70% whereas in patients who 
used 
 
<
 
5ppd it was significantly higher, 94% 
(
 
P
 
 
 
=
 
 0.039). In contrast, VLPP, BMI and age had 
no statistically significant influence on 
success rate (Table1). No differences were 
noticed between success rates of the first and 
last 50 cases (92% vs 90%, 
 
P
 
 
 
=
 
 1).
An additional subanalysis was performed by 
evaluating cure and improvement rates in 
those patients who concluded the 6-month 
and 12-month follow-up visits. At the 6-
month visit, the entire cohort, 105 patients, 
was observed. Eighty-six patients were cured 
(82%) and 11 were improved (10%). The 
KHQ scores of the cured patients for the 
preoperative period and the 6-month 
observation showed a significant reduction, 
consistent with SUI cure. The KHQ subscores 
are displayed in Fig.1. At the 12-month 
visit, 71 patients were available of whom 55 
were cured (77%) and eight were improved 
(11%).
A significant reduction in the mean Q
 
max
 
 
occurred after Mini-Arc
 
TM
 
 placement. Q
 
max
 
 was 
27.0 
 
±
 
 8.7mL/s at baseline and decreased to 
23.7 
 
±
 
 7.5mL/s at 6-month follow-up 
(
 
P
 
 
 
<
 
 0.001).
 
DISCUSSION
 
The data after 12 months of follow-up show a 
success rate of Mini-Arc
 
TM
 
 of 91%, associated 
with a marked overall increase in quality of 
life. Complications were few and mild in 
nature. The surgical procedure was shown to 
be simple and easy to teach and learn by the 
fact that no differences were noticed between 
success rates among the first and last 50 
cases. In addition, no decrease in success rate 
with time was observed.
The definition of cure used in this study 
employed patient-reported outcomes. 
Although the use of subjective criteria for 
cure is frequently overlooked in favour of 
objective tests, as pad weight or cough test, a 
trend supporting subjective evaluations of 
cure is gaining advocates [25]. For cure, a 
statement of no episodes of urine loss and no 
protection use by the patient is particularly 
precise when associated with improvement of 
quality of life determined by an appropriate 
questionnaire [25]. Interestingly, subjective 
criteria may even be more demanding than 
objective parameters, as one can observe from 
the TVT/Burch [6] and RP/TO [26] comparative 
studies, where cure rates based on subjective 
criteria were systematically lower. In addition, 
the usually considered objective criteria may 
lack reproducibility. The cough test is 
frequently negative for incontinence because 
of patient embarrassment. Large intra-
observer and inter-observer variations have 
been reported concerning pad weight [27,28]. 
Hence, the high success rate shown in this 
study, based on patient-reported outcomes 
and quality of life assessment, is strongly 
in favour of the value of the surgical 
procedure.
 
TABLE1 
 
Correlation of stratified 
baseline characteristics 
with percentage of 
improved patients 
(improved and cured)
 
Variable (
 
n
 
) % Improved
 
P
 
 value
Pads per day
 
<
 
2 (16) 93.8 0.039
2–4 (79) 93.7
 
≥
 
5 (10) 70.0
Body mass index
 
<
 
30 (73) 90.3 0.718
 
≥
 
30 (32) 93.8
Age (years)
 
<
 
65 (89) 91.0 1
 
≥
 
65 (16) 93.8
Valsalva leak point pressure
 
<
 
60 (14) 92.9 0.185
60–90 (23) 81.0
 
>
 
90 (68) 93.9
 
FIG.1. 
 
The King’s Health Questionnaire 
scores of the cured patients, 
before and at 6 months after 
placing Mini-Arc
 
TM
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The follow-up of this study is still short. 
Although it includes 71 patients with a 
follow-up time between 12 and 21 months, 
the mean period of observation is 12 months. 
Therefore the study cannot fully respond to 
a pivotal issue when dealing with surgeries 
for the treatment of female SUI, the capacity 
of the procedure to remain effective long-
term is not evaluated. The follow-up of this 
study is far from the experience of 11 years 
with TVT
 
TM
 
 or from the 5-year follow-up of 
the comparative study between TVT
 
TM
 
 and 
Burch colposuspension. It may be argued, 
however, that studies with conventional RP 
and TO slings did not show any meaningful 
decay of efficacy over time. The success rate 
reported by Rinne 
 
etal
 
. [29] in a cohort of 267 
women randomized to TVT
 
TM
 
 or TOT
 
TM
 
 and 
evaluated at a 12-month follow-up was 
unchanged at the 36-month re-evaluation 
[30]. Therefore, many large randomized 
studies comparing RP and TO slings are 
now using 12-month follow-up a as 
reasonable minimum time point for reporting 
the initial results [26,31]. Nevertheless, a 
longer period of close vigilance of the patients 
included in this cohort is obviously mandatory 
before definitive assumptions can be made 
concerning the durability of Mini-Arc
 
TM
 
.
One important goal of SUI management is the 
identification of risk factors negatively 
affecting the cure rate of a particular 
treatment. Commonly admitted risk factors 
such as failure of a previous anti-
incontinence surgery, occurrence of detrusor 
overactivity or the presence of strong urgency 
incontinence before operation could not be 
evaluated [32] in this study because these 
were exclusion criteria adopted in patient 
selection. However, other risk factors were 
investigated including severity of 
incontinence [31], weak sphincter function 
[33] or BMI [34]. Women with more severe 
forms of incontinence (
 
≥
 
5ppd) had less 
chance of being cured or improved (70% if 
 
≥
 
5ppd; 94% if 
 
<
 
2ppd; 94% if 2–4 ppd, 
 
P
 
 
 
<
 
 
0.05). Severity of incontinence was also 
recognized by Rechberger 
 
etal
 
. [31], in their 
series. Women with Stamey type III SUI, which 
was defined as total incontinence or urine loss 
without any relation to physical activity or 
position, was shown to decrease the cure rate 
of TO placed slings but not RP slings [31]. 
Consequently, it is reasonable in future 
studies to restrict Mini-Arc
 
TM
 
 to women with 
mild to moderate forms of SUI. In this context, 
the relevance of sphincter activity was 
surprising. A low VLPP was not found to be a 
risk factor for Mini-Arc
 
TM
 
 failure. In fact, the 
14 women with VLPP 
 
<
 
60cmH
 
2
 
O, indicative of 
ISD, had success rates equivalent to those of 
the global cohort. However, a weak sphincter 
has been recognized as a risk factor to the 
success of TO slings [31,35]. Considering the 
resemblance of Mini-Arc
 
TM
 
 to TO sling 
placement, a word of caution should be 
sounded about the use of this single-incision 
sling in patients with urodynamic evidence of 
ISD before larger studies are conducted.
The BMI is directly associated with the risk for 
SUI [36]. A decrease of weight associated with 
programmed physical activity was shown to 
cure a high percentage of patients with SUI 
[3]. A very high prevalence of SUI is found 
among women attending bariatric surgery 
consultation. Increased intra-abdominal 
pressure results in increased intravesical 
pressure, increased pressure at maximum 
cystometric capacity, and decreased cough 
pressure transmission from the bladder to the 
urethra, which may all contribute to SUI in 
obese patients [37]. As expected, besides 
being found as a risk factor for incontinence, 
morbid obesity (BMI 
 
>
 
 35) has been identified 
as a risk factor for the success of SUI surgery 
[38]. In contrast, a BMI 
 
<
 
 35 seems not to 
influence success rate [39–41]. Likewise no 
influence of BMI could be detected on the 
success rate as one-third of the patients had a 
BMI
 
>
 
30. Yet, we still advise a special 
counselling of overweight women regarding 
Mini-Arc
 
TM
 
 use because deterioration over 
time cannot be totally ruled out at this 
moment.
Mini-Arc
 
TM
 
 becomes fixed by the anchor-like 
extremities inserted in the internal obturator 
muscles. In contrast, conventional suburethral 
slings have a process of fixation that depends 
upon the interaction of a much longer mesh 
with the pelvic floor and abdominal or upper 
tight muscles and fascia, depending on the 
preferred route of placement. Hence, the 
strength of pelvic floor tissues may influence 
single-incision sling fixation more than 
conventional slings. To support this 
assumption, a recent study with TVT-Secur
 
TM
 
 
[15] reported a very poor outcome in patients 
with concomitant pelvic organ prolapses. 
Patient age is another factor that influences 
pelvic floor tissue quality. Nevertheless, the 
success of Mini-Arc
 
TM
 
 in the present study 
was not influenced by age.
Low morbidity is one of the expected 
advantages of single incision slings. Available 
reports indicate that few cases of bladder 
perforation, bowel injury, major bleeding or 
other life-threatening conditions are to be 
expected with single-incision slings [7,9]. This 
study confirms the safety of Mini-Arc
 
TM
 
, as 
the complications reported were few and 
mild. Two points may deserve further 
mention. First, bladder perforation did not 
occur in any woman; if these data are 
confirmed by larger studies, it may be 
appropriate to omit cystoscopy after Mini-
Arc
 
TM
 
 placement. Second, the Mini-Arc
 
TM
 
 
procedure was virtually painless. This is quite 
different from studies on RP or TO slings 
where this complication is commonly 
reported [42].
Although tension-free, Mini-Arc
 
TM
 
 is slightly 
obstructive as a significant decrease in 
urinary free flow was found. However, the 
percentage of 
 
de novo
 
 urgency was low and 
easily manageable medically, suggesting that 
obstruction was clinically irrelevant. Likewise, 
only two cases of high postvoid residual urine 
volume and one case of urinary retention 
occurred after the procedure, which is far less 
than the urinary retention commonly 
reported in series of conventional slings [13]. 
Dyspareunia was mild and transient, probably 
the result of a more superficial insertion of 
the mesh in these cases. However, the 
incidence of dyspareunia in this series is far 
below that reported in TO procedures [43].
The lack of a comparator arm and the follow-
up time being restricted to a mean of 12 
months limit the findings reported here. 
However, they still show that Mini-Arc
 
TM
 
 is a 
reproducible technique, simple to perform 
and easy to learn, that offers high cure rates 
at 1 year follow-up and that is associated 
with few and mild complications. Recent 
initial reports of ongoing trials comparing 
Mini-Arc
 
TM
 
 with conventional slings seem to 
support these results as no differences in 
outcome between Mini-Arc
 
TM
 
 and TO 
conventional slings have been reported 
[44,45].
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Abstract
Background: Contemporary surgical treatment of female stress urinary inconti-
nence (SUI) includes retropubic and transobturator (TO) midurethral slings (MUS).
Case series of single-incision slings (SIS) have shown similar outcomes with lower
morbidity.
Objective: Our aim was to assess the cure rates, complications, and quality-of-life
impact of one standard TO MUS and two SIS.
Design, setting, and participants: Ninety consecutive patients with clinically and
urodynamically proven SUI were enrolled in an exploratory randomised phase 2
trial. Patients with previous SUI surgery, major pelvic organ prolapse, mixed
incontinence, or detrusor overactivity were excluded.
Interventions: Patients were treated randomlywith TVT-O, TVT-Secur, orMini-Arc.
Measurements: Postoperative visits were scheduled at 6 and 12 mo. The King’s
Health Questionnaire (KHQ)was repeated at 6mo. Curewas deﬁned as the absence
of urine leakage, no pad use, and a negative cough test at 12 mo. Pain and other
complications were also investigated.
Results and limitations: Cure rate was 83% after TVT-O, 67% after TVT-Secur, and
87% after Mini-Arc. Improvement was found in 10%, 13%, and 7% of the patients,
respectively. Failures were 7% after TVT-O and Mini-Arc and 20% after TVT-Secur.
TVT-O and Mini-Arc improved at least 15 points in >80% of the patients in six
KHQ domains, whereas TVT-Secur could only achieve improvement in three of the
nine domains. The pain score was lower in theMini-Arc group. Complications were
more numerous after TVT-O. This study has the limitations inherent in a phase 2
trial with a follow-up limited to 12 mo.
Conclusions: Mini-Arc offers cure and improvement rates similar to TVT-O, where-
as TVT-Secur may yield an inferior outcome. These ﬁndings recommend the urgent
launch of large randomised phase 3 studies comparing conventional MUS with SIS,
with Mini-Arc the advised option.
# 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
* Corresponding author. Department of Urology, Hospital de Sa˜o Joa˜o, E.P.E., Alameda Professor
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1. Introduction
Midurethral slings (MUS), either retropubic (RP) or transob-
turator (TO), are the most common contemporary surgical
treatment for female stress urinary incontinence (SUI). Two
facts have largely contributed to this situation: (1) Without
compromising incontinence cure rate, RP MUS cause less
morbidity and shorter hospital stays than the Burch
colposuspension [1], and (2) RP and TO MUS have been
shown repeatedly to have equivalent success rates [2,3].
Nevertheless, neither is free of complications, mainly
dictated by the blind course of the introducer devices. The
RP coursemayperforate the bladder,whereas the TOpassage
is associated with vaginal perforation and neurologic
impairment leading to protracted thigh pain and upper leg
weakness [4]. Both routes occasionally are associated with
life-threatening complications including bowel perforation,
major vessel disruption, and perineal gangrene [5]. In
addition, voiding dysfunction and vaginal mesh exposures
may also complicate MUS [6].
The quest to minimise the morbidity of MUS has
determined the appearance of yet another group of shorter
MUS, requiring a single vaginal incision for placement.
Available data, mainly from case series [7,8], validate
that assumption. However, reported success rates are
extremely variable, ranging between 40% [9] and 100%
[10], suggesting that considerable differences exist among
single-incision slings (SIS) in what concerns efficacy. In spite
of this evidence, comparative studies of SIS have not been
performed up to now.
Our exploratory study assessed two SIS, TVT-Secur
(Gynecare; Ethicon Inc., Somerville, NJ, USA) and Mini-
Arc (American Medical Systems, Minnetonka, MN, USA),
and TVT-O (Gynecare; Ethicon Inc., Somerville, NJ, USA), a
conventional TO MUS. Cure and complication rates and
quality of life were investigated at 6- and 12-mo follow-up.
Previous results were presented elsewhere [11].
2. Patients and methods
We enrolled consecutive patients from our surgical waiting list with
clinically and urodynamically proven SUI associated with urethral
hypermobility between January and September 2008. The three slings
investigated in the study were available in the hospital and could be
indicated for any of the patients included. No patients refused
randomisation. All patients gavewritten informed consent before entering
the trial, which was authorised by the Ethics Committee of Hospital
Sa˜o Joa˜o, Porto, Portugal.
Preoperative evaluation included a medical history comprising
urogynaecologic andneurologic assessments andaurodynamicevaluation
following International Continence Society recommendations [12,13].
Body mass index was determined according to the World Health
Organisation deﬁnitions [14]. Cystometry and valsalva leak point pressure
(VLPP; using intravesical pressure, measured in the lithotomy position,
with the bladder ﬁlled at the normal desire to void) were performed.
Intrinsic sphincter deﬁciency (ISD) was considered if VLPP was <60 cm
H2O [15].
Women with previous surgeries for SUI, genital prolapse stage 2
(by the Pelvic Organ Prolapse Quantiﬁcation System), complaints of
urgency, frequency, nocturia, or demonstrating detrusor overactivitywere
excluded.
Impact of SUI on the quality of life was assessed by the King’s Health
Questionnaire (KHQ) score [16]. A 15-point reduction in each domainwas
considered indicative of improvement. The surgeries were performed by
the authors with the patient in the lithotomy position, with hips ﬂexed at
908. All the surgeons had a minimum experience of 30 cases for each
procedure. For prophylactic antibiotherapy, intravenous ceftriaxone 1 g
was used. A 16F Foley catheter was introduced and urine evacuated.
TVT-O was inserted according to De Leval [17]. TVT-Secur was
positioned in the hammock position [7,18]. The Mini-Arc procedure
followed the original description [8,19]. The surgical incisions were
closed with a 3-0 running suture, and a vaginal gauze was left in place.
Postoperative analgesia included paracetamol (1 g orally three times
a day) and ibuprofen (400 mg orally three times a day). On postoperative
day 1, the vaginal gauze and the Foley catheter were removed and
residual volume measured after spontaneous voiding (postvoiding
residual). If<100 ml, patients were discharged on paracetamol 1 g orally
three times a day. At discharge (postoperative day 1), womenwere asked
to rate the pain they felt in the ﬁrst 24 h, in spite of the standard
analgesic protocol, using a 0–10 visual analogue scale.
Postoperative evaluations included visits at 6 and 12mo following the
procedure and were performed between January and September 2009.
Patients were asked about lower urinary tract symptoms including urine
leakage, pain, and complications. KHQ was repeated at the 6-mo visit. A
cough test, at the volume the patient referred to as a normal desire to void,
was performed at 12 mo.
Patients were considered cured if they did not report any episodes of
urine leakage, ceased to wear any incontinence protection, and had a
negative cough test. If a patient reportedmaintenance of SUI or a positive
cough test, but the number of incontinence protections necessary
decreased by >50% and she answered afﬁrmatively to the question ‘‘Are
you satisﬁed with the result of the surgery?’’, the patient was considered
improved. All other cases were deemed failures. When used, the term
success rate indicates the sum of cure and improvement rates.
Previous case series have shown that success rates after conventional
TOMUS vary from 35% to 98% [20]; success rates reported after Mini-Arc
and TVT-Secur vary from 40% to 100% [7,9,10,19]. Sample size was
computed considering a one-stage procedure by Fleming. A minimum of
26 patients in each group was needed assuming a higher proportion for
acceptance of 0.85, a lower proportion for rejection of 0.6, an a of 0.05,
and a b of 0.1.
3. Results
Table 1 lists the demographics and baseline characteristics
of the groups. No patients were lost to follow-up. Five
patients had a VLPP slightly below 60 cm H2O. However,
surgeons maintained the surgical option because they
believed the most important component for SUI was
urethral hypermobility. One patient was randomised for
TVT-O (VLPP: 59 cm H2O), two for TVT-Secur (VLPP: 58 cm
H2O each), and two for Mini-Arc (VLPP: 54 cm H2O and
58 cm H2O).
At the 12-mo evaluation, 25 of 30 patients (83%) were
cured and 3 of 30 patients (10%)were improved after TVT-O.
After TVT-Secur, these numbers were 20 of 30 patients
(67%) and 4 of 30 patients (13%), respectively. After Mini-
Arc, these numbers were 26 of 30 patients (87%) and 2 of 30
patients (7%), respectively. Failures were 2 of 30 patients
(7%) after TVT-O and Mini-Arc and 6 of 30 patients (20%)
after TVT-Secur (Fig. 1).
TVT-O and Mini-Arc improved >80% of patients by a
minimum of 15 points in six of the nine KHQ domains
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(incontinence impact, role limitation, physical limitation,
emotion, sleep, severity). TVT-Secur improved >80% of
patients by a minimum of 15 points in three KHQ domains
(physical limitation, emotion, severity) and very close to
80% in another three (role limitation, sleep, and social
limitation) (Fig. 2).
No cases of intraoperative major bleeding, haematuria,
urethral injury, or vaginal perforation were observed. No
immediate associated surgical procedure was required.
Pain score in the first 24 h had its maximum expression
in TVT-O and its minimum in Mini-Arc, and it was
intermediate in TVT-Secur (Table 2). Nine patients submit-
ted to TVT-O had some form of complication, and this MUS
was, in fact, the sole one that had complications requiring
surgical interventions. These surgeries, performed in two
patients, consisted of sling transection due to recurrent
urinary retention, carried out through a vaginal approach.
Five patients developed moderate de novo urgency; two
had referred prolonged thigh pain. Concerning TVT-Secur,
complications occurred in five patients with one transient
urinary retention, one urinary tract infection, and three
cases of de novo moderate urgency. Mini-Arc was
associated with six complications with one transitory
urinary retention, one urinary tract infection, three cases of
[()TD$FIG]
Fig. 2 – Percentage of patientswith at least 15 points of improvement on the King’s Health Questionnaire (KHQ) domains at 6mo after placement of each tape.
GHP = global health perception; Impact = incontinence impact; Role = role limitation; Phys = physical limitation; Soc = social limitation; Pers = personal
limitation.
Table 1 – Baseline demographics and clinical characteristics of the enrolled patients
TVT-O TVT-Secur Mini-Arc
No. 30 30 30
Age, yr
Mean  SD 52.0  11.7 52.7  10.9 52.6  11.8
Median (range) 52 (38–74) 52 (33–72) 51.5 (29–66)
BMI
Mean  SD 27.2  5.3 26.3  6.6 29.8  5.4
Median (range) 27.0 (20.5–38.9) 26.2 (20.2–41.1) 29.1 (22.2–43.3)
Pads per day
Mean  SD 3.1  2.0 2.5  1.3 2.5  1.8
Median (range) 3 (1–12) 2 (1–9) 2 (1–15)
Parity
Mean  SD 1.5  1.1 1.8  2 2.1  2.2
Median (range) 2 (1–4) 2 (0–5) 2 (1–4)
Years of onset
Mean  SD 10.8  8.5 8.4  5.9 8.0  6.1
Median (range) 10 (3–20) 6 (2–20) 8 (1–18)
VLPP
Mean  SD 109  18.5 82  39 95  41
Median (range) 105 (59–142) 83 (58–126) 93.5 (54–166)
BMI = body mass index; SD = standard deviation; VLPP = Valsalva leak point pressure.
[()TD$FIG]
Fig. 1 – Cure, improvement, and failure rates after each midurethral sling
at 12-mo follow-up.
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de novo urgency, and one case of prolonged pain in the
thigh.
4. Discussion
This phase 2 study evaluated two SIS, TVT-Secur and Mini-
Arc, and TVT-O, a conventional TO MUS, as first surgical
treatment for SUI. Data merit two considerations. First, all
testedMUS had success rates above the minimum cut-off of
60%. Second, only TVT-O and Mini-Arc overtook the higher
cut-off for acceptance.
The in-out TO sling TVT-O was chosen as the standard
device due to its resemblance to TVT-Secur and Mini-Arc
techniques. The option for TVT, the only MUS compared
with Burch colposuspension [1], would introduce the
possibility of complications only dictated by the retropubic
passage of the needles [3]. In addition, the success rates
achieved by RP and TO MUS in patients without ISD are
identical [2,3]. As the standard technique, the 93% success
rates observed here with TVT-O were similar to those of
other studies at 12-mo follow-up. Zullo et al reported an
89% success rate [21], and Rinne et al reported a 93% cure
rate [22]. The most common complications, de novo
urgency, pain in the thigh, and urinary retention, were
also similar to those reported elsewhere [2,3,6].
The 93% success rate attained here with Mini-Arc was
identical to that of TVT-O. It should also be stressed that our
success rate is in line with those previously reported also
after 12-mo follow-up. In a prospective case series, Moore
et al reported a cure rate of 91% based on a negative cough
stress test (n = 61) [8]. Debodinance and Delporte found a
success rate of 90% (n = 68) [23]. In the twomost recent and
largest case series, Kennelly et al (n = 157) reported a
negative cough test in 91% of the patients [13], and Oliveira
et al (n = 105) accounted for a success rate of 91% [24].
Comparisons between conventional MUS and Mini-Arc are
still sparse. De Ridder and Berkers compared Mini-Arc
(n = 75) to Monarc (American Medical Systems, Minne-
tonka, MN, USA) (n = 56) in a retrospective study [25]. The
objective cure rate of 85% at 12 mo was similar with both
MUS. These data diverge, however, from those of Basu and
Duckett, who randomly assigned 61 patients either to Mini-
Arc or to a RP sling (Advantage TVT; Boston Scientific,
Natick, MA, USA) [26]. At 6 mo, a failure rate of 41% was
found in the Mini-Arc group as opposed to only 3% in the RP
sling arm [26]. The limited previous experience of the
authors with the TO route may explain such difference,
already detected at the first follow-up visit at 6 wk [26].
Thus it may be concluded that the harpoon-like anchoring
extremities, once inserted in the internal obturator muscle,
provide a grip equivalent to TVT-O. In the latter, fixation is
obtained by the passage through the internal obturator
muscle, obturator membrane, external obturator, and thigh
muscles.
In contrast to Mini-Arc, TVT-Secur offered a success rate
of 80%, lower than that observed with the other two MUS.
Failures with TVT-Secur amounted to 20%, that is, almost
three times higher than in the other groups. In agreement,
TVT-Secur only improved (at least 15 points) in >80% of
patients in three of the nine KHQ domains. In available case
series, TVT-Secur cure rates are highly variable. Our own
initial TVT-Secur experience with 105 patients showed
success and failure rates at 15 mo similar to those found
here [7]. Meschia et al reported similar success rates on 95
patients at 15mo [27]. Cornu et al, with amean follow-up of
30 mo (n = 45), reported a success rate of 58% [9]. In
contrast, in the sole comparative study published up to date,
TVT-Secur and TVT-O provided similar outcomes with a
cure rate of 83% for TVT-Secur and 81% for TVT-O [28]. The
fact that TVT-Secur has been associated with lower success
rates deserves some consideration. TVT-Secur has a long
learning curve [20]. Even among experienced surgeons,
consistent positioning of the TVT-Secur tip may be difficult.
Correct placement in some studieswas<50% [29].Moreover,
mesh detachment from the introducer blades requires a
twisting movement that may enlarge the internal obturator
muscle area where the TVT-Secur tip was inserted,
compromising mesh adhesion.
The study confirmed the lowmorbidity of SIS. Pain in the
first 24 h was very low in the Mini-Arc group, whereas it
was rated four times higher in the TVT-O arm. TVT-O was
associated with two cases of urinary retention requiring
sling transection. On the contrary, only one case of transient
urinary retention occurred in the two SIS patient groups.
Two patients in the TVT-O group reported prolonged
referred thigh pain. This complication was not observed
in the TVT-Secur arm. However, SIS may not be totally
exempt from this complication because one patient in the
Mini-Arc group complained of thigh pain for 6 mo. As in
TVT-O, inadvertent violation of the obturator membrane,
nerve lesioning, or haematoma formation could have been
the cause of this problem [6]. However, it must represent a
rare event because prolonged pain complaints had never
been reported with Mini-Arc before [8,13,23–25].
This study has the inherent limitations of phase 2 trials,
mainly a small number of patients and a relatively short
follow-up time of 12 mo. Although this follow-up time is
commonly used in studies investigating the outcome of
conventionalMUS [2,3], it might be desirable to evaluate SIS
at considerably longer follow-up times. Nevertheless, this
study clearly indicates the need to conduct well-powered
multicentre randomised clinical trials comparing SIS with
standard techniques. According to the present results, Mini-
Arc should be chosen to be further compared against TO
slings. Such comparative studies should probably be
compulsory before the introduction of new devices for
SUI treatment. A uniform report of outcomes, stating cure
and improvement rates, would facilitate comparisons.
Table 2 – Postoperative pain score in first 24 h, assessed at
discharge by a 0–10 visual analogue scale
TVT-O TVT-Secur Mini-Arc
Postoperative pain
Mean  SD 4.5  2.6 2.3  2.3 1.0  1.0
Median (range) 4 (1–10) 3 (0–6) 1 (0–3)
SD = standard deviation.
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5. Conclusions
SISmayoffer success rates for SUI equivalent to conventional
TO MUS with less morbidity. These exploratory findings
shouldbe further investigated inrandomisedphase3studies.
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We cannot agree more with Professors Costantini and
Lazzeri in their editorial [1], as, in our opinion, they touch on
three essential points. First, there is the need to adequately
compare new devices with a gold standard technique to
have sound scientific support ahead of their widespread use
for the treatment of female stress urinary incontinence.
There is no valid reason to have looser rules for the
introduction of slings than for the introduction of new
drugs. Second, rigorous and reproducible methods of
assessing outcomes must be standardized and obligatory
in all published studies, so high-quality evidence can be
adequately drawn. These outcome assessments should
include objective and subjective (patient-reported out-
comes) efficacy evaluations as well as quality-of-life
questionnaires. Third, it should bemandatory to investigate
materials used to ensure that they remain safe, as they will
stay in patients’ bodies for many years, most probably the
remainder of their lives.
Our contribution is modest [2], but we think these phase
2 studies are crucial in defining which of the new devices
should be further compared with standard techniques in
well-powered phase 3 clinical trials. Only at this point, if
scientific evidence is adequate, should the new devices be
available in everyday clinical practice.
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Single-incision slings were introduced in the surgical treatment of female stress urinary incontinence (SUI) to lessen the morbidity
associated with traditional midurethral slings. However, long-term reports on patient satisfaction are still scarce. This study
describes the outcome of women treated with Mini-Arc at a mean follow-up of 45 months. In a previous report on 105 women
with 15-month mean follow-up, 84 (80%) were found cured and 12 (11%) improved. Now, with a mean follow-up of 45 months,
cured/improved patients were reassessed by telephone and completed Patient Global Impression of Improvement (PGI-I), Patient
Global Impression of Severity (PGI-S), rated their improvement in a 0–100 scale, and answered if they would recommend the
procedure. At 45-month follow-up, 73 women cured/improved were available for evaluation. Over 80% of the cured patients rated
the improvement of SUI by the PGI-I as “very much better” or “much better,” reported their urinary tract condition to be “normal”
on PGI-S, and described their improvement >70%. Ninety percent would recommend this procedure to a friend. The improved-
patient population is very small (𝑛𝑛 𝑛 𝑛𝑛. This study shows that the majority of patients cured/improved after Mini-Arc placement
maintain a high degree of satisfaction at a long-term evaluation.
1. Introduction
According to the European Association of Urology Guide-
lines on Urinary Incontinence, concerning the treatment
of female stress urinary incontinence (SUI), the retropu-
bic insertion of a midurethral synthetic sling (MUS) gives
equivalent patient-reported cure of SUI at 12 months, when
compared to colposuspension [1]. These guidelines also
report that midurethral synthetic sling inserted by either the
transobturator (TO) or retropubic (RP) route gives equivalent
patient-reported outcome at 12 months [1].
With an obvious trending towards less and less invasive
surgical options, single-incision vaginal slings (SIS) have
emerged. They require very limited intracorporeal dissec-
tion, proposing to further increase safety of suburethral
slings, without jeopardizing the success rates reported by
conventional RP and TO access [2]. These SIS outcomes are
comparable with conventional MUS at short-term follow-
up [3–5]. Although sparse, two-year follow-up studies are
available and seem to maintain steady success rates over this
time [6, 7]. Longer follow-up time reports are needed, to
ensure that, in the long run, these SIS offer constant success
rates.
The objective of this study is to describe the outcome
of women treated with Mini-Arc at a mean follow-up of 45
months, based on a baseline population which has already
been reported in a short-term paper [8], after adequate long-
term follow-up evaluation. Previously considered cured and
improved patients were evaluated to access if their condition
remains stable, as reflected in a subjective satisfaction evalu-
ation.
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Figure 1: Study subject distribution tree.
2. Materials and Methods
This is a single-centre prospective evaluation of women
with urodynamic stress urinary incontinence, which were
submitted to Mini-Arc (American Medical Systems, Min-
netonka, MN, USA) placement as a primary surgical treat-
ment. Surgical technique, inclusion and exclusion criteria,
baseline population characteristics, and short-term outcome
and complications have already been described in a previous
paper [8]. On this report, on 105 women with a mean follow-
up of 15 months (and a minimum follow-up of 6 months),
84 patients (80%) were found cured and 12 (11%) improved.
Now, with a mean follow-up of 45 months, cured/improved
patients were reassessed by telephone interview and com-
pleted Patient Global Impression of Improvement (PGI-I), to
access treatment response [9], Patient Global Impression of
Severity (PGI-S), to access current SUI condition [9], rated
their improvement in a 0–100 scale, and answered if they
would recommend the procedure. This study was approved
by the institutions’ ethics committees and each participant
provided written informed consent prior to enrollment.
3. Results and Discussion
At 15-month mean follow-up (initial population of 105
patients), 84 patients were cured and 12 improved. Seventy-
seven patients could be contacted (80% of the initial pop-
ulation) and have a current mean follow-up of 45 months
(median 43.5 months). Four had to be excluded due to
cognitive impairment. Three were submitted to other forms
of SUI treatment during the period of follow-up. So, from
a total of 77 responders, 70 (91%) maintained the initial
cure/improvement situation (Figure 1). Subsequently, 63 pre-
viously considered cured and 7 improved were available for
analysis.
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Figure 2: Patient Global Impression of Improvement (PGI-I).
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Figure 3: Patient Global Impression of Severity (PGI-S).
Fifty-three of the cured patients (84%) rated the improve-
ment of SUI by the PGI-I as “very much better” or “much
better” and 4 (6%) considered it to be “a little better.” Four
patients (6%) answered “no change” and two (3%) “a little
worse” (Figure 2). The mean rate of improvement in a 0–
100 scale was 81 ± 15, 52 patients (83%) rating improvement>70. Fifty-four patients (86%) reported their urinary tract
condition (UTC) to be “normal” on PGI-S (Figure 3). Fifty-
seven (90%) would recommend this procedure to a friend.
When analyzing improved patients (𝑛𝑛 𝑛 𝑛), 2 (29%)
considered their PGI-I as “very much better” or “much
better,” 1 (14%) “a little better,” and 4 (57%) “no change”
(Figure 2). Only 3 patients (43%) rated their improvement
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to be equal or superior to 70% in a 0–100 score or would
recommend the procedure to a friend. Five patients (71%)
answered “moderate” on PGI-S, with only two patients (29%)
considering their UTC to be “normal” (Figure 3).
Female urinary incontinence is a very common condi-
tion, which can affect around 35% of women; SUI is the most
prevalent type, but the consultation and treatment rates are
very low [10].
The conservative management is the first treatment
option and it usually includes pelvic floor muscle training,
which can be very successful in around a fourth of the
patients, especially in younger patients with mild forms of
the condition [11]. Obese women can adopt a program of
weight reduction associated with physical exercise, which
can offer a 25% cure rate, since they stay firmly devoted
to the program over time and are willing to wait for the
improvements [12]. As a result, surgery is the most common
form of SUI treatment worldwide. During the last 2 decades
we have observed the development of promising SUI surgical
techniques and the introduction of suburethral, tension-
free slings. TVT (Gynecare, Ethicon, Somerville, New Jersey,
USA) was the first device of this kind to be introduced in
clinical practice, in 1996 by Ulmsten et al. [13].
According to the European Association of Urology
Guidelines on Urinary Incontinence, the RP insertion of a
MUS gives equivalent patient-reported cure of SUI at 12
months, when compared to colposuspension [1]. Nonethe-
less, TVT shows low invasiveness, short hospital stay, reduced
risk of prolonged catheterization, and low risk of causing
future pelvic organ prolapsed [14]. All together, these charac-
teristics were responsible for the swift replacement of Burch
colposuspension as the preferred surgical approach to female
SUI [14]. TVT has become the gold standard in the surgical
treatment of SUI with high cure rates that subsist at long
time follow-up [15].The blind passage of needles through the
RP space was associated with severe complications, such as
bladder and bowel perforations and life-threatening vascular
injuries [16, 17].These concerns led to the development of the
TO route in 2000, a relatively avascular space for the passage
of trocars [18]. However, TO tapes have been associated with
prolonged and limitative pain referred to the groin and upper
thigh, due to the obturator foramen violation and vaginal
perforations due to a more horizontal trajectory of the needle
passage [16, 17, 19].
To our knowledge, this is the longest follow-up prospec-
tive report onMini-Arc single-incision sling. At roughly four-
year follow-up, the majority of patients cured or improved at
short-term evaluation maintain a high degree of satisfaction
at long term.
Short- and midterm reports on Mini-Arc have, on the
majority, been consistent with the initial results of this series
[6, 7] and comparable to conventional MUS [20, 21], with a
low morbidity profile [20, 21].
The number of patients available for this evaluation, with
80% responders at almost 4-year mean follow-up, permits
having an adequate idea of the long-term outcomes of the
initial population, in a reliable way.
Patient Global Impression of Improvement questionnaire
addresses the SUI treatment outcomes when compared with
baseline condition and the results among the cured patients
describe a 90% (57 patients) positive result, with 84% of the
patients considering their actual condition to be “very much
better” or “much better,” which is usually assumed to be equal
to a cured situation. These numbers are certainly reliable,
as the 0–100 improvement scale results mean score is over
80%, with over than 4/5 of the cured patients rating this
improvement >70%. On the other way, the actual urinary
tract condition, addressed by PGI-S, is considered “normal”
by 86% of the cured women. Only 10% of the cured women
did not recommend the procedure to a friend.
The improved-patient population is very small (𝑛𝑛 𝑛7), and interpreting their results would not prompt solid
conclusions.
These reports on long-term evaluation are very important
to assure that SIS are a valid technique, with fair and
comparable results at short- and middle-term evaluations,
and that over time the results are maintained stable.
4. Conclusions
This study shows that the majority of patients cured/impro-
ved after Mini-Arc placement maintain a high degree of sati-
sfaction at a long-term evaluation.
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DISCUSSION 
 
 The ideal MUS should be simple to place, require short hospital stay, a 
quick return to active life, have rare and mild complications, be reproducible and 
give a high success rate. The studies included in this thesis clearly show that 
SIS can be considered a safe and promising option for SUI treatment. The final 
positioning of SIS among the surgical alternatives for SUI treatment is, however, 
unknown and was not the objective of this study. This work should be 
interpreted as an initial insight, which now must be followed by many other 
studies, meta-analysis and, at last, by the test of time. 
 
DIFFERENT SINGLE-INCISION VAGINAL SLINGS, DIFFERENT OUTCOMES  
 
 Our prospective case series reporting on TVT-SecurTM, on a short-term 
follow-up, showed it as a minimally invasive procedure, with less complications 
than those reported after similar case-series on traditional MUS, either peri-
operative, either post-operative (Oliveira et al, 2009). To be mentioned no 
bladder perforation, major bleeding, or persistent groin pain occurred. However, 
the percentage of dry patients was only slightly over 70%, lower than Mini-ArcTM 
or TVT-OTM. We have advanced some issues regarding this procedure 
reproducibility, although in our hands the long-term results were reasonable 
(Silva et al, 2010). However, two recent meta-analysis on SIS, carried out in 
2011 and 2014 demonstrated a general poor outcome of this SIS (Abdel-Fattah 
et al, 2011a and Mostafa et al, 2014). In addition, the TVT Worldwide Registry 
Investigators (Tincello et al, 2011) compared TVTTM, TVT-OTM and TVT-SecurTM 
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Investigators (Tincello et al, 2011) compared TVTTM, TVT-OTM and TVT-SecurTM 
(both vertical and horizontal routes) in a multicentre trial, recruiting more than 
1300 patients. Almost half of them received the SIS procedure. TVT-OTM was 
more efficacious than the other comparators, with failure rates reaching 3.6% 
for TO, 12.8% for RP and 15.8% for SIS (p=0,0039). Taken together, these 
studies led the manufacturer to withdraw TVT SecurTM from the market. 
 
Following our short-term prospective evaluation of Mini-ArcTM, which 
showed a dry rate of 80% and global success over 90%, with consistent QoL 
related improvements and minor morbidity (Oliveira et al, 2011a), fully 
confirmed by other cohort studies (Kennelly et al, 2010 and Pickens et al, 
2011), we launched the first comparative study between Mini-ArcTM and other 
slings (Oliveira et al, 2011b). In a total of 90 women, Mini-ArcTM was shown to 
be as effective as the conventional TO MUS, but with much less complications, 
mainly post-operative pain, urinary retention requiring surgical revision or 
transient voiding dysfunction (Oliveira et al, 2011b). As mentioned above, Mini-
ArcTM was more effective than TVT-SecurTM (Oliveira et al, 2011b). This pilot 
study was corroborated by the SIMS Italian Group, which compared 3 SIS, and 
also favored Mini-ArcTM versus the others (p<0,05) in terms of patient’s 
satisfaction and versus TVT-SecurTM in the morbidity profile (p<0,05) (Palomba 
et al, 2012 and 2014). Also, Mini-ArcTM showed a significantly (p<0.05) higher 
feasibility to be performed under local anesthesia and in ambulatory setting 
(Palomba et al, 2012 and 2014). 
The longest prospective follow-up currently available for Mini-Arc TM is 
the prolonged evaluation of our series (Oliveira et al, 2014), with a mean follow-
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the initial follow-up (12 months) maintained a high degree of satisfaction, as 
assessed subjectively on 73 patients. Only 3 patients were submitted to other 
SUI treatments (4%). These data are consistent with other author’s 
observations (Kennelly et al, 2012 and Moore et al, 2013). 
The meta-analysis by Mostafa et al (2014) showed that Mini-ArcTM is 
equivalent to conventional MUS in terms of objective cure rates. 
 
MORBIDITY AND COMPLICATIONS OF SINGLE-INCISION VAGINAL SLINGS 
 
The recent meta-analysis (Mostafa et al, 2014), concluded that SIS are, 
indeed, a major evolution in female anti-incontinence surgery. This study 
confirmed that SIS, once TVT-SecurTM is excluded, offer quicker operative 
times, less post-operative pain, faster return to normal activities and to work. 
Also, SIS are associated with less groin pain and a tendency towards less post-
operative voiding difficulties. Even though, SIS are associated with more 
probability of vaginal tape erosion and need for repeated anti-incontinence 
surgery, although these data were contaminated by TVT-SecurTM data.  
Lopes et al (2011), further explored the cohort used in our RCT (Oliveira 
et al, 2011b) in order to investigate the impact of sling surgeries on female 
sexual function. Applying the questionnaire FSFI (Female Sexual Function 
Index), it was concluded that there were no differences between SIS and 
conventional MUS. Mostafa et al (2014), in a meta-analysis that included 2 
studies addressing this matter, withdrew the same conclusion. 
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BEYOND TVT-SECURTM AND MINI-ARCTM 
 
Although the initial reports with Tissue Fixation System (TFSTM) were 
quite enthusiastic, no more relevant data was published. 
AjustTM (Bard Urological Division, Covington, GA, USA) is a new SIS, 
consisting of an adjustable mesh with polypropylene anchor-like extremities, 
designed to consistently place the sling in the obturator membrane. It was 
commercialized after the beginning or our studies, a fact that prevented us from 
including it in our work. It consists of a sub-urethral mesh and an adjustable 
mesh; (Bard Medical Division, 2009). Initial 12 months reports were only 
recently published. A 2011 report (Abdel-Fattah et al, 2011b) on 90 patients, 
showed a 80% subjective cure rate and reduced morbidity, in a painless 
procedure. Cornu et al (2012) involved 95 women in their case-series and, at a 
mean range of 21 months, showed a success rate of 80% (no wet pads), with 
minimal morbidity. Although SIS suggest the gain obtained from the fast 
recovery of patients to their normal and active life is obvious, there are not 
many studies that account for the economical benefits of SIS. One study, 
however, has shown that AjustTM, performed under local anesthesia, as an out-
patient procedure, was more cost-effective than TVT-OTM with up to 1 year 
follow-up (Boyers et al, 2013). The meta-analysis by Mostafa et al (2014) 
already includes an evaluation of AjustTM, with consistent results eliciting it as 
an evolution towards mini-invasiveness and cost-effectiveness. 
SolyxTM sling system (Boston Scientific Corporation, Natick, MA, USA) 
has a similar design to Mini-ArcTM, but the available data (pilot RCT) do not 
permit, yet, any firm conclusion. 
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Contasure NeedlelessTM and OphiraTM Mini Sling System (Promedon, 
Córdoba, Argentina) are SIS that do not user anchor-like fixation methods. 
Although they seem effective, data are scarce, and their results should be 
interpreted with caution. 
Mini-ArcTM Precise is the newer version of Mini-ArcTM, with exactly the 
same anchoring system, that is designed to be easily adjustable during 
insertion. By maintaining the fixation anchor on the extremity of the insertion 
needle till the final positioning of the mesh, Mini-ArcTM Precise has gradually 
replaced the previous design. 
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CONCLUSIONS 
 
Single-incision vaginal slings are here to stay. The simplicity of the 
procedures, associated with safety and efficacy are highly attractive for many 
surgeons and patients. Our work shows beyond any doubt that SIS cannot be 
looked at as one single type device. Currently, SIS that offer robust fixation 
systems, particularly hook-like ones, seem to provide the most efficacious 
results, concerning success rates (Mostafa et al, 2014). This is the case of Mini-
ArcTM and AjustTM. Any new SIS or equivalent device should be, nevertheless, 
adequately compared with conventional MUS, in order to clearly define its 
efficacy, safety and cost-effectiveness. Only then, should these new devices be 
commercially available.  
One important point still to define is the long-term results of SIS as form 
of treatment for SUI. The meta-analysis by Mostafa et al (2014), although 
assuming the maturity of these devices, warned about the relatively short 
follow-up time, 18 months only. This issue can only be solved by the test of time 
and adequate follow-up of available cohorts. 
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SUMMARY 
 
This work investigates the efficacy and safety of single-incision vaginal 
slings (SIS) for the treatment of female stress urinary incontinence.  
Two SIS were investigated, the TVT-SecurTM and Mini-ArcTM. Both were 
studied in prospective cohorts, including long-term evaluations and in a phase 2 
randomized clinical trial, in which these SIS were compared with a conventional 
mid-urethral sling. 
We concluded that SIS are easy to insert and extremely safe. However, 
TVT-SecurTM, due to its complex design, may offer some difficulties to position, 
raising questions about reproducibility. 
In terms of efficacy, Mini-ArcTM, with its harpoon-like fixation system, 
offers cure rates comparable to the gold standard mid-urethral slings. Its 
effectiveness was confirmed up to 4 years after implantation. 
In contrast with Mini-ArcTM, TVT-SecurTM provides lower cure rates of SUI 
than traditional mid-urethral slings. In part, the poorer outcome of TVT-SecurTM 
is related to the fixation system, which is a Velcro-like extremity that needs to 
interact with host tissues. 
In conclusion, SIS with robust anchoring systems are a promising 
treatment of female SUI. 
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RESUMO 
 
 Este trabalho investigou a eficácia e segurança das fitas sub-uretrais de 
incisão única vaginal no tratamento da incontinência urinária de esforço 
feminina. 
 Foram investigadas duas fitas sub-uretrais de incisão única vaginal, o 
TVT-SecurTM e o Mini-ArcTM. Ambas foram estudadas em séries prospectivas, 
incluindo avaliações a longo prazo e um ensaio clínico randomizado de fase 2, 
no qual estas fitas foram comparadas com uma técnica convencional. 
 Este trabalho concluiu que as fitas sub-uretrais de incisão única vaginal 
são fáceis de colocar e extremamente seguras. No entanto, o TVT-SecurTM, 
devido à sua concepção mais complexa, pode oferecer mais dificuldades para 
um adequado posicionamento, levantando questões no que diz respeito à sua 
reproducibilidade. 
 Em termos de eficácia, o Mini-ArcTM, com as suas extremidades em 
arpão, permite taxas de cura comparáveis às técnicas padrão. A sua eficácia 
foi confirmada até aos 4 anos após a cirurgia. 
 Em contraste com o Mini-ArcTM, o TVT-SecurTM tem taxas de cura de 
incontinência urinária de esforço inferiores às fitas convencionais. Em parte, os 
piores resultados do TVT-SecurTM estão relacionados com o seu mecanismo de 
fixação, cuja extremidade exerce um efeito tipo Velcro, necessitando de 
interagir com os tecidos da doente. 
 Em conclusão, as fitas sub-uretrais de incisão única vaginal com 
mecanismos de ancoragem robustos são um tratamento promissor para a 
incontinência urinária de esforço feminina. 
